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Non-alcoholic fatty liver disease (NAFLD) 
is a disease spectrum in which excess fat 
accumulates in the liver. NAFLD often 
coexists with obesity, metabolic syndrome 
and type 2 diabetes (’Metabolic NAFLD’) 
and is characterised by insulin resistance. 
NAFLD may also be due to common gene 
variants in PNPLA3 at rs738409 and 
TM6SF2 at rs58542926. It is unclear 
whether these forms of ‘Genetic NAFLD’ 
are related to insulin resistance. Liver fat 
content may be assessed using liver 
histology, imaging tools or biomarkers. 
This thesis was undertaken to better 
understand the pathogenesis of NAFLD 
and to improve currently available 
diagnostic tools. 
 
Subcutaneous (SC) adipocyte hypertrophy 
is associated with insulin resistance, but it 
is unknown whether SC adipocyte size is 
independently associated with liver fat 
content. In study I, mean adipocyte size 
was determined from a SC adipose tissue 
obtained from 119 non-diabetic subjects, 
whose liver fat content was measured 
using proton magnetic resonance 
spectroscopy (1H-MRS). SC adipocyte size 
significantly associated with liver fat 
content independent of age, gender, 
measures of body composition and 
PNPLA3 genotype (R2=54%, p<0.0001). 
 
In study II, a systematic review was 
conducted to investigate whether 
‘PNPLA3 NAFLD’ and ‘TM6SF2 NAFLD’ 
are associated with insulin resistance. In 
12 of 14 studies, the carriers of the 
PNPLA3 I148M variant had higher liver 
fat content than the non-carriers without 
an increase in insulin resistance, while in 
5 of 7 studies, the carriers of the TM6SF2 
E167K variant had higher liver fat content 
than the non-carriers without an increase 
in insulin resistance. A systematic review 
was also performed to compare how 
normal liver fat content is defined by liver 
histology and currently available imaging 
tools: 1H-MRS, magnetic resonance 
imaging, computed tomography and 
ultrasound. The definitions of normal liver 
fat content were found to be variable and 
not inter-relatable. 
 
In study III, a reference value for a 
surrogate marker of insulin resistance, 
HOMA-IR, was determined, its use in the 
diagnosis of NAFLD evaluated and inter-
laboratory variation determined. The 
study cohorts included two population-
based studies, the FINRISK 2007 
(n=5024) and the FIN-D2D (n=2849), 
and a cohort of 368 non-diabetic subjects 
who underwent measurement of liver fat 
content using 1H-MRS. In the healthy 
subjects of FINRISK (n=1167) and FIN-
D2D (n=459), the upper reference limits 
for HOMA-IR (the 95th percentile [95% 
CI]) were 1.9 (1.8–2.0) and 2.0 (1.9–2.1), 
respectively. The former corresponded to 
the optimal HOMA-IR cut-off for 
diagnosing NAFLD (AUROC 0.88, 
sensitivity 85%, specificity 80%). The 
latter matched with a HOMA-IR 
corresponding to normal liver fat content 
(5.56%). Inter-laboratory variation of 
HOMA-IR was determined by 
simultaneously analysing samples from 10 
subjects in 7 European laboratories. The 
coefficient of variation of HOMA-IR was 
high, 25%. 
 
In study IV, we determined whether 
serum pIGFBP-1, which is produced 
mainly by the liver and regulated by 
insulin, helps in the estimation of liver fat 
content independent of other known 
predictors of liver fat content. Fasting 
serum pIGFBP-1 was measured in 378 
subjects who underwent measurement of 
liver fat content using 1H-MRS. Serum 
pIGFBP-1 significantly associated with 
liver fat content independent of age, 
waist-to-hip ratio, and fasting ALT, 
glucose and insulin. This model, ‘% Liver 
fat equation’, was significantly worse 
when pIGFBP-1 was removed (p<0.05) 
and significantly better than liver enzymes 
ALT and AST (p<0.0001). 
Abstract    
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In summary, SC adipocyte size is an 
independent factor contributing to 
variation in liver fat content. ‘Genetic 
NAFLD’ seems not to be characterised by 
insulin resistance despite larger amounts 
of liver fat. Definitions of normal liver fat 
depend on the diagnostic imaging method 
used and are not inter-related. The upper 
reference limit of HOMA-IR corresponds 
to normal liver fat content, but high inter-
laboratory variation must be considered. 
Measurement of pIGFBP-1 may help in 
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Non-alcoholic fatty liver disease (NAFLD) 
is a disease spectrum ranging from simple 
steatosis (non-alcoholic fatty liver, NAFL) 
and non-alcoholic steatohepatitis (NASH) 
to cirrhosis. NAFLD is strongly associated 
with obesity, type 2 diabetes and the 
metabolic syndrome (MetS) (‘Metabolic 
NAFLD’), and with increasing prevalence, 
has become the most common cause of 
chronic liver disease in the Western 
countries (Younossi et al., 2011). 
 
’Metabolic NAFLD’ can be considered a 
systemic disease, as it is associated with 
insulin resistance not only in the liver, but 
also in adipose tissue and skeletal muscle. 
A fatty liver is resistant to the action of 
insulin to suppress production of glucose 
and triglycerides, leading to 
hyperinsulinemia, hyperglycaemia, hyper-
triglyceridemia and low concentrations of 
high-density lipoprotein (HDL) cholesterol 
concentrations (Yki-Järvinen, 2014). In 
adipose tissue, insulin fails to suppress 
lipolysis, resulting in an increase of free 
fatty acid (FFA) flux to the liver. Insulin-
resistant adipose tissue is characterised by 
inflammation and altered secretion of 
adipokines (Hoffstedt et al., 2004). Insulin 
resistance has also been associated with 
enlarged fat cells but how adipocyte cell 
size relates to NAFLD is unknown. 
 
Given that insulin resistance characterises 
‘Metabolic NAFLD’, measurement of 
insulin sensitivity might be helpful in 
diagnosing NAFLD in clinical practice. The 
homeostasis model assessment of insulin 
resistance (HOMA-IR) is calculated by 
multiplying the fasting glucose 
concentration with that of insulin 
(Matthews et al., 1985). This measure is an 
excellent surrogate of insulin resistance in 
non-diabetic subjects in whom insulin 
secretion readily responds to increases in 
fasting glucose concentrations. The 
reference values for HOMA-IR and 
particularly its relationship to liver fat 
content have not been established nor have 
insulin assays been standardised across 
different laboratories. 
 
In addition to glucose, the liver produces 
most serum proteins. Ideally one would 
like to identify proteins which are 
regulated by insulin and which are 
exclusively produced by the liver. Our 
laboratory has previously shown that one 
such factor is the insulin-like growth factor 
binding protein-1 (IGFBP-1) (Kotronen, 
Lewitt, et al., 2008). It is unknown 
whether measuring its major circulating 
form, phosphorylated IGFBP-1 (pIGFBP-
1), improves diagnosis of ‘Metabolic 
NAFLD’ compared to routinely available 
markers. 
 
In 2008, a common variant in the patatin-
like phospholipase domain-containing 3 
(PNPLA3) (rs738409 [G], encoding 
I148M) was found to predispose to NAFLD 
(Romeo et al., 2008). Individuals carrying 
this genetic variant have increased liver fat 
content, but seem not to be insulin 
resistant and therefore not at increased 
risk of type 2 diabetes or cardiovascular 
diseases. One would therefore predict that 
this variant might influence the 
relationship between liver fat content and 
HOMA-IR, but this has not been studied. 
This may also be the case for another 
recently described genetic risk factor for 
NAFLD i.e. rs58542926 [T], which encodes 
E167K in the transmembrane 6 
superfamily member 2 (TM6SF2) gene 
(Kozlitina et al., 2014). 
 
The studies in the present series were 
undertaken to better understand the 
pathogenesis of NAFLD and to improve 
currently available diagnostic tools. In 
study I, we were particularly interested in 
understanding whether subcutaneous 
adipocyte size is associated with liver fat 
independent of other factors, such as age, 
gender and obesity. Studies II–IV 
addressed diagnostic tools. We 
systematically reviewed the literature 
  Introduction 
	
  13   
regarding existing definitions of normal 
liver fat, and associations between insulin 
sensitivity and ‘Genetic NAFLD’ (II). We 
wished to define reference values for 
HOMA-IR based on two population-based 
cohorts and the relationship of HOMA-IR 
to liver fat content in subjects whose liver 
fat content had been measured using 
proton magnetic resonance spectroscopy 
(1H-MRS), the state-of the art method to 
quantify liver fat content (III). Finally, we 
explored the utility of measuring pIGFBP-1 
in the diagnosis of NAFLD (IV). 




2 REVIEW OF THE 
LITERATURE 
 




NAFLD is defined as hepatic steatosis not 
caused by excess alcohol intake (>30g/day 
in men and >20g/day in women), hepatitis 
B or C, autoimmune hepatitis, iron 
overload, or use of drugs or toxins 
(Chalasani et al., 2012). NAFLD is in fact a 
disease spectrum that ranges from simple 
steatosis and NASH to cirrhosis (Chalasani 
et al., 2012). NASH is characterised, in 
addition to steatosis, by ballooning 
necrosis, mild inflammation and possibly 
fibrosis, and can only be diagnosed by liver 
biopsy (Brunt et al., 2011).  
 
Although NAFLD frequently coexists with 
obesity, insulin resistance, type 2 diabetes 
and the and other conditions associated 
with the MetS (‘Metabolic NAFLD’) 
(Anstee and Day, 2013), common genetic 
forms of NAFLD also exist (‘Genetic 
NAFLD’). A variant in patatin-like 
phospholipase domain-containing 3 
(PNPLA3) (rs738409 [G], encoding 
I148M) increases the risk of NAFL, NASH 
and fibrosis (‘PNPLA3 NAFLD’) (Romeo et 
al., 2008; Sookoian and Pirola, 2011). 
Genetic variation in transmembrane 6 
superfamily member 2 (TM6SF2) 
(rs58542926 [T], encoding E167K) is also 
associated with higher liver fat content and 
increased risk of NASH and cirrhosis 
(‘TM6SF2 NAFLD’) (Dongiovanni et al., 
2015; Kozlitina et al., 2014). Most recently, 
genetic variation in membrane bound-O-
acyltranserase domain-containing 7 
(MBOAT7) (rs641738 [T]) has been 
associated with increased risk of steatosis, 
NASH and fibrosis (‘MBOAT7 NAFLD’) 
(Mancina et al., 2016). 
 
 
2.1.2. Prevalence and significance 
 
NAFLD has become the most common 
cause for chronic liver disease, causing 
47% to 75% of chronic liver disease in 1988 
to 2008, respectively (Younossi et al., 
2011). According to a recent meta-analysis, 
the global prevalence of NAFLD is 25% 
(Younossi et al., 2016). The prevalence, 
however, is highly variable around the 
world, as it ranges from 13% in Africa, 24% 
in Europe and North America, 28% in Asia, 
30% in South America to 32% in the 
Middle East (Younossi et al., 2016). 
NAFLD is found in 60% to 70% of patients 
with type 2 diabetes (Targher et al., 2007; 
Williamson et al., 2011) and up to 85% of 
morbidly obese subjects undergoing 
bariatric surgery (Beymer et al., 2003; 
Gholam et al., 2002; Morita et al., 2015). 
NAFLD has become the third most 
common cause of liver transplantation in 
the United States (Marchesini and 
Mazzotti, 2015). 
 
The prevalence of NASH ranges from 3% 
to 6% (Anstee and Day, 2013; Vernon et 
al., 2011). NASH is found in 10% to 20% of 
subjects with NAFLD (Adams et al., 2005; 
Vernon et al., 2011). In longitudinal 
studies, fibrosis stage, but no other 
features of NASH, is independently 
associated with overall mortality, liver 
transplantation and other liver-related 
events (Angulo et al., 2015; Ekstedt et al., 
2015). In a 33-year follow-up, subjects with 
NAFLD had increased mortality compared 
to a reference population, and a higher risk 
of death from cardiovascular disease, 
infectious diseases, cirrhosis and 
hepatocellular carcinoma (HCC) (Ekstedt 
et al., 2015). Interestingly, while the 
activity of NASH did not predict mortality, 
fibrosis stage did predict both overall and 
disease-specific mortality (Ekstedt et al., 
2015).  
 
Unlike previously thought, simple steatosis 
can also progress to NASH and clinically 
significant fibrosis (McPherson et al., 
2015; Pais et al., 2011; Wong et al., 2010). 
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During a 5-year follow-up, NASH 
developed in 2% to 3% of those with NAFL, 
and cirrhosis developed in 8% of those 
with NASH (Adams et al., 2005; Vernon et 
al., 2011). Fibrosis progression is slower in 
NAFL compared to NASH, as fibrosis 
progressed one stage in 14.3 years in 
subjects with NAFL, compared to one stage 
in 7.1 years in subjects with NASH (Singh 
et al., 2015).  
 
NAFLD increases the risk of type 2 
diabetes, chronic kidney disease and 
cardiovascular disease (Anstee and Day, 
2013). NAFLD also increases the risk of 
HCC, especially in patients with cirrhosis 
(Michelotti et al., 2013) but also without 
cirrhosis (Ertle et al., 2011). According to 
the National Cancer Registry in Finland, 
there are 470 to 500 new liver cancer 
diagnoses yearly (Syöpärekisteri, 2016). 
HCC accounts for 85% to 90% of all 
primary liver cancers (El-Serag and 
Rudolph, 2007), and assuming NAFLD is 
the cause of HCC in 5% to 20% of cases in 
Western countries (Michelotti et al., 2013), 
there are approximately 16 to 90 new 
NAFLD-related HCC diagnoses yearly in 
Finland.  
 




Overall, men are more susceptible to 
NAFLD than women (Browning et al., 
2004; Pan and Fallon, 2014; Williams et 
al., 2011; Zhu et al., 2015). If classified 
according to body mass index (BMI), lean 
subjects (BMI <25 kg/m2) with NAFLD are 
more often women, whereas overweight 
(BMI 25–30 kg/m2) and obese (BMI <30 
kg/m2) subjects are more often men 
(Younossi et al., 2012). For a given BMI, 
men have higher lean mass as well as more 
intra-abdominal (IA) and hepatic fat, 
whereas women have greater subcutaneous 
(SC) adipose depots (Geer and Shen, 
2009). In cases of a similar amount of liver 
fat, women have more SC adipose tissue 
and a higher BMI than men (Kotronen, 
Westerbacka, et al., 2007). The correlation 
between liver fat and IA fat is similar in 
men and women, even though women have 
more SC adipose tissue (Kotronen, 





The prevalence of NAFLD increases with 
age (Adams et al., 2005; Ong et al., 2008; 
Park et al., 2006). In a recent meta-
analysis, the prevalence of NAFLD was 
22% to 27% in under the age of 50 years 
and 34% in subjects of 70-79 years of age 
(Younossi et al., 2016). Older individuals 
have more risk factors for NAFLD and 
present with more severe biochemical and 
histological changes (Frith et al., 2009). 
Subjects with NAFLD cirrhosis are 
significantly older than those with milder 
disease (Frith et al., 2009). Alarmingly, 
young age does not protect one from 
NAFLD. Population-based studies have 
found that the global prevalence of 
paediatric NAFLD is 3%, and that the 
prevalence of NAFLD in obese children 
ranges from 10% to 77% (Barshop et al., 
2008). 
 
2.1.3.3. Obesity and the metabolic 
syndrome 
 
Obesity is strongly associated with NAFLD. 
In an analysis of liver histology from liver 
donors, automobile crash victims, autopsy 
findings and clinical liver biopsies, the 
prevalence rates of steatosis and NASH 
have been approximated to be 15% and 3%, 
respectively, in non-obese subjects; 65% 
and 20%, respectively, in obese subjects; 
85% and 40%, respectively, in morbidly 
obese subjects (BMI ≥40 kg/m2) (Fabbrini 
et al., 2010). A meta-analysis of 12 studies, 
consisting of 1620 morbidly obese subjects 
undergoing bariatric surgery, found the 
prevalence of steatosis, NASH and 
unexpected cirrhosis to be 91% (range 85–
98%), 37% (24-98%) and 1.7% (1–77%), 
respectively (Machado et al., 2006). On the 
other hand, a recent meta-analysis 
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estimated the prevalence of obesity to be 
51% and 82% in subjects with NAFLD and 
NASH, respectively (Younossi et al., 2016). 
 
MetS is a cluster of metabolic 
abnormalities that are either causes or 
consequences of insulin resistance, and 
that coexist commonly in obese subjects 
(Yki-Järvinen, 2014). The diagnosis of 
MetS requires at least three of the 
following criteria: increased fasting plasma 
(fP)-glucose or diagnosis of type 2 
diabetes, hypertriglyceridemia, low 
concentrations of high-density lipoprotein 
(HDL) cholesterol, increased waist 
circumference (ethnicity dependent) or 
hypertension (Alberti et al., 2009). NAFLD 
is closely related to all components of the 
MetS (Adams et al., 2009; Adiels et al., 
2008; Kotronen, Westerbacka, et al., 
2007; Marchesini et al., 2001; 2003). 
NAFLD has been shown to predict 
development of type 2 diabetes in 20 
prospective studies independent of age and 
obesity (Lallukka and Yki-Järvinen, 2016).  
 
NAFLD can also be found in lean 
individuals, and they are at increased risk 
of type 2 diabetes and MetS compared to 
lean subjects without NAFLD (Feng et al., 
2014). In a population-based study, 
compared to lean subjects without NAFLD, 
lean subjects with NAFLD were more 
commonly Hispanic, and had type 2 
diabetes and hypertension (Younossi et al., 
2012). However, compared to obese 
subjects with NAFLD, lean subjects with 
NAFLD are younger and present with 
fewer components of MetS (Younossi et al., 
2012). As discussed below, neither 
‘PNPLA3 NAFLD’ (Sookoian and Pirola, 
2011) nor ‘TM6SF2 NAFLD’ (Sookoian et 
al., 2015) seem to be associated with 
obesity. These gene variants are therefore 
of interest when searching for causes of 
NAFLD in lean subjects with NAFLD.  
 
2.1.3.4. Race and ethnicity 
 
NAFLD is the most frequent in Hispanics 
and East Asian Indians and least common 
in African Americans (Browning et al., 
2004; Petersen et al., 2006; Schneider et 
al., 2013; Williams et al., 2011). These 
differences are in part explained by the 
difference in frequencies of known risk 
genotypes such as the PNPLA3 I148M 
variant (Romeo et al., 2008), as well as 
differences in body fat distribution and 
body composition among the different 
ethnic groups. For example, in cases of 
similar BMI, Asians have more visceral fat 
and less lean body mass compared to 
Caucasians (Dudeja et al., 2001; WHO 
Expert Consultation, 2004) and Hispanics 
and Caucasians have more visceral fat than 
African Americans despite similar BMI and 
waist circumference (Carroll et al., 2008). 
Chinese have more liver fat for a given BMI 
than Caucasians (Xia, Yki-Järvinen, et al., 
2016). 
 
2.1.3.5. Dietary factors and physical 
inactivity 
 
Excess energy intake increases the risk of 
NAFLD (Bo et al., 2014). It seems that 
particularly diets containing excess 
carbohydrates or saturated fatty acids 
(FAs) increase liver fat content and 
deteriorate insulin sensitivity (Yki-
Järvinen, 2015). Saturated FAs seem to be 
more harmful to the liver than 
polyunsaturated FAs (Bjermo et al., 2012; 
Parks et al., 2017). 
 
Regarding physical activity, a population-
based study including 3056 subjects 
examined the relationship between NAFLD 
and physical activity assessed by 
accelerometer readings over 7 days. 
Subjects with NAFLD (diagnosed using the 
Fatty Liver Index (Bedogni et al., 2006)) 
were less physically active than those 
without NAFLD (Gerber et al., 2012). On 
the other hand, lifestyle modifications — 
weight reduction and/or increased physical 
activity — consistently reduced liver fat 
and improved glucose control and insulin 
sensitivity in 23 lifestyle intervention 
studies (Thoma et al., 2012). The data on 
improvement of histopathology is still 
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scarce, but suggestive that steatohepatitis 
might improve (Thoma et al., 2012; Vilar-
Gomez et al., 2015). 
 
2.1.3.6. Genetic risk factors of NAFLD 
 
The association between NAFLD and 
genetic variation in PNPLA3 at rs738409 
[G], encoding I148M, was first reported in 
2008 (Romeo et al., 2008) and has since 
been replicated multiple times (Kotronen, 
Johansson, et al., 2009; Sookoian and 
Pirola, 2011; Xu et al., 2015; Zhang et al., 
2015). The gene variant is common with an 
allele frequency ranging from 20% to 50% 
depending on ethnicity (Romeo et al., 
2008). In a meta-analysis, carriers of the 
PNPLA3 I148M variant had 73% more liver 
fat, a 3.3-fold higher risk of NASH and a 
3.3-fold greater risk of developing fibrosis 
than the non-carriers of the variant 
(Sookoian and Pirola, 2011). A meta-
analysis of 12 Asian studies found the risk 
of NAFLD to be increased by 2-fold in 
carriers compared to non-carriers (Zhang 
et al., 2015). Recent meta-analyses have 
also shown that the PNPLA3 I148M 
variant increases the risk of liver cirrhosis 
by 2-fold (Shen et al., 2015) and the risk of 
HCC by 2-fold (Trépo et al., 2014). 
 
In 2014, genetic variation in TM6SF2 at 
rs58542926, encoding E167K, was found to 
increase the risk of NAFLD independent of 
genetic variation in PNPLA3 at rs738409, 
degree of obesity and alcohol intake 
(Kozlitina et al., 2014). The allele 
frequency of the TM6SF2 E167K variant is 
less than that of the PNPLA3 I148M 
variant, ranging from 7.2% in Caucasians 
and 4.7% in Hispanics to 3.4% in African 
Americans (Kozlitina et al., 2014). A meta-
analysis found carriers of TM6SF2 E167K 
to have a 2-fold higher risk of developing 
NAFLD than non-carriers (Pirola and 
Sookoian, 2015). In addition to increasing 
the risk of steatosis, several studies have 
found the TM6SF2 E167K variant to also 
confer an increased risk of NASH, liver 
fibrosis and cirrhosis compared to non-
carriers (Dongiovanni et al., 2015; Eslam 
et al., 2016; Liu et al., 2014). 
 
Most recently, in 2016, a single nucleotide 
polymorphism C>T in MBOAT7 at 
rs641738, was shown to increase the risk of 
steatosis in a population-based cohort of 
2736 subjects, and risk of steatosis, NASH 
and liver fibrosis in 1149 subjects who had 
undergone liver biopsy (Mancina et al., 
2016). In the population-based multiethnic 
cohort, the risk of NAFLD was increased in 
Caucasians but not in African or Hispanic 
Americans (Mancina et al., 2016). The 
variant allele is common, with an allele 
frequency ranging from 33% to 46%, 
depending on ethnicity (Mancina et al., 
2016). 
 
2.2. PATHOGENESIS OF NAFLD 
 
2.2.1. ‘Metabolic NAFLD’ 
 
As discussed above, the prevalence of 
NAFLD is closely linked to features of 
MetS, obesity and insulin resistance (Lazo 
et al., 2013). Insulin resistance can be 
defined as a condition where the response 
to one or several actions of insulin is 
blunted. As discussed below, insulin 
resistance is an essential feature of 
‘Metabolic NAFLD’ (Yki-Järvinen, 2014). 
NAFLD is associated with insulin 
resistance at the level of the whole body 
(Marchesini et al., 2001), in the liver 
(Seppälä-Lindroos et al., 2002), in skeletal 
muscle (Bugianesi, Gastaldelli, et al., 
2005; Marchesini et al., 2001) and in 
adipose tissue (Bugianesi, Gastaldelli, et 
al., 2005; Kotronen, Vehkavaara, et al., 
2008; Ryysy et al., 2000). 
 
2.2.1.1. Normal glucose metabolism 
 
Maintenance of normal glucose 
homeostasis relies on simultaneous 
regulation of glucose production and 
utilisation in the fasted and postprandial 
state. After an overnight fast, the liver is 
the exclusive source of glucose, which is 




either newly synthetized via gluco-
neogenesis or released from hepatic 
glycogen via glycogenolysis (Owen et al., 
1969). The main action of insulin after an 
overnight fast is to restrain hepatic glucose 
production (Yki-Järvinen, 1993). Glucagon 
counteracts this inhibitory effect of insulin 
(Cherrington et al., 1987). After an 
overnight fast, glucose is utilised mainly by 
the brain in a non-insulin dependent way 
(DeFronzo et al., 1983).  
 
Under postprandial conditions, the 
combined effects of hyperglycaemia, 
increase in insulin and decrease in 
glucagon secretion suppress endogenous 
glucose production and stimulate glucose 
uptake by the splanchnic organs (gut, liver) 
and utilisation by the peripheral tissues 
(Kelley et al., 1988). The main energy 
source of insulin-dependent tissues after a 
meal is glucose rather than FFAs, due to 
insulin-induced inhibition of lipolysis and 
stimulation of glucose uptake (Yki-
Järvinen, 1993). After an oral glucose load, 
approximately one third is taken up by 
splanchnic tissues, and one fourth by 
muscle tissue and the brain (Kelley et al., 
1988). 37% of the oral glucose load is 
oxidised, mainly by brain and muscle 
tissues, and 63% is stored, mainly by 
splanchnic and muscle tissues (Kelley et 
al., 1988). 
 
2.2.1.2. Insulin resistance of glucose 
metabolism in the liver 
 
Liver fat content is inversely correlated 
with suppression of hepatic glucose 
production, a marker of hepatic insulin 
resistance, in subjects with (Kotronen, 
Vehkavaara, et al., 2008) and without 
(Kotronen, Vehkavaara, et al., 2007; 
Marchesini et al., 2001; Ryysy et al., 2000; 
Seppälä-Lindroos et al., 2002) type 2 
diabetes. This correlation remains 
significant after adjustment for BMI and 
waist-to-hip ratio (Seppälä-Lindroos et al., 
2002). 
2.2.1.3. Insulin resistance of glucose 
metabolism in skeletal muscle 
 
The ability of insulin to stimulate glucose 
uptake in skeletal muscle is impaired in 
subjects with NAFLD compared to subjects 
without NAFLD (Bugianesi, Gastaldelli, et 
al., 2005; Kotronen, Seppälä-Lindroos, et 
al., 2008; Marchesini et al., 2001), and the 
correlation is inverse and linear with 
increasing liver fat content (Korenblat et 
al., 2008). 
 
2.2.1.4. Normal lipid metabolism 
 
After an overnight fast, triglycerides in 
adipose tissue are hydrolysed by hormone-
sensitive lipase (HSL) and other lipases. 
FFAs are released into the plasma and 
taken up by the liver and other tissues such 
as skeletal and heart muscles. In the liver, 
FAs are preferentially oxidised (Frayn et 
al., 2006). FFAs are the major substrate 
for intrahepatocellular triglycerides after 
an overnight fast (Lambert and Parks, 
2012). Insulin inhibits lipolysis by 
inhibiting HSL and the oxidation FAs 
(Frayn et al., 2006). 
 
After a meal, dietary fat is hydrolysed in 
the gut lumen by intestinal lipases, taken 
up by enterocytes and repackaged into 
chylomicron (CM) lipoprotein particles. 
These are secreted into the lymph and then 
enter the circulation (Lambert and Parks, 
2012). Most triglycerides in CM (CM-TG) 
are hydrolysed by lipoprotein lipase (LPL) 
in peripheral tissues, and stored as 
triglycerides in adipose tissue after re-
esterification. The remaining CM-
remnants are taken up by the liver (Frayn 
et al., 2006). A portion of FAs released in 
hydrolysis of CM-TG spill over into plasma 
and provide substrates for liver triglyceride 
synthesis (Lambert and Parks, 2012). 
 
Hepatic FAs are derived from dietary FAs 
from CM-remnants, lipolysis of peripheral 
triglycerides from adipose tissue or de 
novo lipogenesis (DNL) in the liver (Frayn 
et al., 2006). In the liver, FAs are diverted 
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towards β-oxidation, ketone body 
production or triglyceride and other 
glycerolipid synthesis. A part of stored 
triglycerides is secreted into circulation in 
very low-density lipoprotein (VLDL) 
particles. In the liver, uptake of FFAs 
seems to depend mainly on delivery (Frayn 
et al., 2006). Secretion of VLDL particles is 
acutely suppressed by insulin (Adiels et al., 
2007). 
 
2.2.1.5. Insulin resistance of lipid 
metabolism in the liver 
 
Excess triglyceride storage in the liver may 
be a consequence of excess FFAs entering 
the liver, increased DNL or impaired FFA 
oxidation and ketogenesis. Defects in 
VLDL synthesis and secretion could also 
contribute to steatosis as in familial 
hypobetalipoproteinemia (Amaro et al., 
2010). These abnormalities in triglyceride 
handling are not necessary or sufficient to 
cause insulin resistance, as triglycerides 
themselves are inert, but rather excessive 
accumulation of FA-derived lipid 
metabolites is lipotoxic (Matsuzaka and 
Shimano, 2011; Samuel and Shulman, 
2012). 
 
As discussed below, increased FFA release 
from adipose tissue contributes to 
increased liver fat content. In ‘Metabolic 
NAFLD’, studies using stable isotopes have 
shown that FAs are also produced in excess 
via DNL (Diraison et al., 2003; Donnelly et 
al., 2005; Lambert et al., 2014). In fasted, 
lean individuals, less than 5% of FAs of 
triglycerides in VLDL (VLDL-TG) originate 
from DNL as compared to subjects with 
NAFLD, in whom up to 20% of the FAs in 
VLDL-TG originate from DNL (Diraison et 
al., 2003; Donnelly et al., 2005). DNL 
produces saturated FAs (Aarsland and 
Wolfe, 1998), which have been shown to be 
increased in the circulation of subjects with 
NAFLD (Westerbacka et al., 2010: Orešič 
et al., 2013). In insulin-resistant subjects 
with NAFLD, the liver lipidome is 
markedly enriched with saturated and 
monounsaturated FAs, as well as 
dihydroceramides and ceramides, which 
are synthesised from saturated FAs 
(Luukkonen, Zhou, Sädevirta, et al., 2016). 
Ceramides are bioactive and impair insulin 
signalling (Summers, 2006). 
 
Secretion of VLDL-TG serves as a 
mechanism for liver to reduce liver fat 
content. Hepatic insulin resistance is 
characterised by a defect in insulin 
inhibition of VLDL production. In subjects 
with NAFLD, the liver overproduces 
triglyceride-rich VLDL particles in the 
fasting state (Adiels et al., 2006) and 
during hyperinsulinemia (Adiels et al., 
2007). This leads to hypertriglyceridemia 
and low HDL cholesterol concentration 
(Syvänne and Taskinen, 1997). 
 
Indirect measures of hepatic lipid 
oxidation, assessed by plasma 3-
hydroxybutyrate concentration, suggest 
that hepatic lipid oxidation is unchanged 
in subjects with NAFLD compared to 
subjects without NAFLD in the fasted state 
and in euglycaemic hyperinsulinemia 
(Kotronen, Seppälä-Lindroos, et al., 2009). 
 
2.2.1.6. Insulin resistance in adipose tissue  
 
Adipose tissue triglyceride storage is 
stimulated and mobilisation suppressed by 
insulin. Suppression of adipose tissue 
lipolysis is extremely sensitive to insulin 
(Nurjhan et al., 1986). In insulin-resistant 
adipose tissue, release of FFAs and glycerol 
into circulation is increased. Insulin-
mediated suppression of lipolysis is 
impaired in overweight subjects with 
NAFLD compared to lean, age- and 
gender-matched, healthy controls 
(Marchesini et al., 2001). The ability of 
insulin to suppress lipolysis closely 
correlates with liver fat content in subjects 
with and without type 2 diabetes 
(Gastaldelli et al., 2007; Kotronen, 
Seppälä-Lindroos, et al., 2008; Kotronen, 
Vehkavaara, et al., 2008). Thus, increase 
in adipose tissue lipolysis causes an 
increase in the supply of FFA to the liver.




Gene expression of FAT/CD36, which 
increases FFA uptake from plasma to cells, 
is increased in the liver and skeletal 
muscle, but decreased in adipose tissue of 
obese subjects with NAFLD compared to 
obese subjects without NAFLD (Fabbrini et 
al., 2009; Greco et al., 2008). This could 
contribute to FFA storage outside adipose 
tissue. 
 
Abdominal obesity, e.g. accumulation of fat 
in the visceral or IA fat depot, is better 
correlated with hepatic steatosis and MetS 
than with overall obesity (Kotronen, 
Westerbacka, et al., 2007). Liver fat 
content is significantly and positively 
correlated with IA and SC adipose tissue 
volume (Kotronen, Westerbacka, et al., 
2007). According to the ‘portal hypothesis’, 
visceral adipose tissue releases excess FFA 
into the portal vein and exposes the liver to 
high FFA concentrations (Frayn et al., 
2006). However, hepatic venous 
catheterisation studies have shown that 
only 5% and 20% of splanchnic FFA uptake 
originate from visceral fat in lean and 
obese subjects, respectively, and the 
contribution increases as visceral fat mass 
increases (Nielsen et al., 2004). Thus, the 
main source of FFA entering the liver is the 
peripheral SC fat depot (Nielsen et al., 
2004). 
 
2.2.1.6.1. Adipose tissue inflammation  
 
Adipose tissue consists mostly of 
adipocytes, but also includes a stromal-
vascular fraction (SVF) of preadipocytes, 
fibroblasts, vascular endothelial cells and a 
variety of immune cells. While the main 
role of adipose tissue is to store energy as 
lipids, it is also an active endocrine organ 
that secretes various hormones, such as 
leptin and adiponectin, and a variety of 
bioactive peptides, that are known as 
adipokines (Kershaw and Flier, 2004). 
They act both locally in an 
autocrine/paracrine fashion and 
systemically in an endocrine fashion 
(Kershaw and Flier, 2004). In addition to 
these efferent signals, adipose tissue 
expresses a multitude of receptors that 
allows it to respond to hormonal and 
neural stimuli (Kershaw and Flier, 2004). 
At least 600 adipokines have been 
identified (Dahlman et al., 2012; Lehr et 
al., 2012). They regulate immune 
responses, inflammation, glucose and lipid 
metabolism, insulin sensitivity, appetite 
and satiety, and other biological processes 
(Blüher 2012). Two types of adipose tissue 
exist – the white adipose tissue which 
stores energy, and brown adipose tissue 
which generates body heat (Virtanen and 
Nuutila P, 2011). This thesis focuses on 
white adipose tissue. 
 
Adipose tissue inflammation has been 
proposed to play an important role in 
obesity-related insulin resistance (Blüher, 
2016; Heilbronn and Campbell, 2008). 
Many of the adipokines, including 
monocyte chemotactic protein-1 (MCP-1), 
tumour necrosis factor-α (TNF-α), 
interleukin-1 (IL-1), IL-6 and IL-8, have 
been reported to promote insulin 
resistance (Lackey and Olefsky, 2016). In 
2003, Weisberg et al. found, first in mice 
and subsequently in humans, that the 
number of macrophages in adipose tissue 
is increased in obesity (Weisberg et al., 
2003). Along with this, it has been shown 
in mice that obesity induces a phenotypic 
switch in macrophages from an anti-
inflammatory M2 polarisation state to a 
pro-inflammatory M1 polarisation state 
(Lumeng et al., 2007). Accumulation of M1 
macrophages in adipose tissue has been 
shown to result in secretion of a variety of 
pro-inflammatory cytokines, such as TNF-
α and IL-6, as well as chemokines, such as 
MCP-1, that can exert local paracrine 
actions to decrease insulin signalling 
(Lackey and Olefsky, 2016) and potentially 
induce adipose tissue inflammation and 
insulin resistance (Shoelson et al., 2007). 
These pro-inflammatory factors may leak 
out of adipose tissue into the circulation 
and promote insulin resistance in other 
peripheral tissues (Osborn and Olefsky, 
2012). In contrast, it has been shown in 
mice that M2-polarised macrophages 
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participate in the remodelling of adipose 
tissue, including the clearance of dead or 
dying adipocytes and the recruitment and 
differentiation of adipocyte progenitors 
(Lee et al., 2013).  
 
In humans, the number of macrophages is 
increased in the adipose tissue of obese 
subjects, as compared to lean subjects, as 
well as in the adipose tissue of subjects 
with NAFLD, as compared to that of 
weight-matched subjects without NAFLD 
(Kolak et al., 2007). Weight loss decreases 
macrophage infiltration and pro-
inflammatory gene expression in the 
adipose tissue of obese subjects (Clément 
et al., 2004). Furthermore, in a study of 
113 morbidly obese subjects undergoing 
bariatric surgery, subjects with NAFLD 
and NASH have an increased expression of 
genes that regulate inflammation in their 
visceral and SC adipose tissue, and 
increased circulating cytokines and 
chemokines such as TNF-α, IL-8 and MCP-
1 (du Plessis et al., 2015). 
 
2.2.1.6.2. Adipocyte cell size  
 
In obesity, adipose tissue expands by 
increasing the number of adipocytes 
(hyperplasia) or the size of the adipocytes 
(hypertrophy), or a combination of both 
(Arner and Spalding, 2010). Hypertrophy 
is characteristic of all overweight and obese 
subjects whereas hyperplasia correlates 
more strongly with the severity of obesity 
and is most marked in morbidly obese 
individuals (Arner and Spalding, 2010; 
Hirsch and Batchelor, 1976). The 
relationship between SC adipocyte size and 
body fat mass is curvilinear in men and 
women (Spalding et al., 2008). It has been 
suggested that there is a ‘critical adipocyte 
size’ that would trigger a subsequent 
increase in adipocyte number (Arner and 
Spalding, 2010). This could be because the 
capacity of adipocytes to store lipids is 
limited (Virtue and Vidal-Puig, 2010). 
When this ‘critical adipocyte size’ limit is 
reached, the tissue must generate more 
adipocytes to be able to expand further 
(Hirsch and Batchelor, 1976; Virtue and 
Vidal-Puig, 2010). After weight loss, 
adipocyte volume decreases, but the 
number of adipocytes fails to decrease 
(Spalding et al., 2008).  
 
In earlier in vitro studies, large adipocytes 
were less insulin sensitive than small 
adipocytes (Salans et al., 1973; Smith, 
1971). Adipocyte size is also an important 
determinant of the expression and 
secretion of several pro-inflammatory 
adipokines, as larger adipocytes secrete 
higher amounts of pro-inflammatory 
mediators (leptin, IL-6, IL-8, MCP-1) and 
less of anti-inflammatory or insulin 
sensitizing factors such as adiponectin and 
IL-10 (Skurk et al., 2007). Larger 
adipocytes are also more prone to store 
lipophilic toxins, which may increase 
intracellular stress, autophagy and 
apoptosis (Haim et al., 2015; Kosacka et 
al., 2015). With increasing adipocyte size 
and limited expandability of adipose tissue, 
local hypoxia may also contribute to 
adipose tissue inflammation (Trayhurn, 
2013). 
 
Cross-sectional human studies have found 
SC adipocyte size to have a strong positive 
correlation with adipose tissue 
inflammation and whole-body insulin 
resistance independent of body 
composition or BMI (Lundgren et al., 
2007; Maffeis et al., 2007; Weisberg et al., 
2003). Increased SC adipocyte size has 
been shown to be associated with 
metabolic impairments such as 
dyslipidemia (Rydén et al., 2014), 
hypertension (Ledoux et al., 2009) and 
markers of insulin resistance (Arner and 
Spalding, 2010; Björntorp and Sjöström, 
1971; Cotillard et al., 2014; Lundgren et al., 
2007; Maffeis et al., 2007) independent of 
body composition (BMI or body fat 
percentage). Reports on correlation 
between SC adipocyte size and insulin 
resistance in subjects with type 2 diabetes 




are contradictory. Lundgren et al. found no 
correlation between SC adipocyte size and 
insulin resistance in 49 subjects with type 
2 diabetes (Lundgren et al., 2007), but did 
find that the diabetic subjects had larger 
SC adipocyte size than 83 BMI-matched 
non-diabetic subjects. SC adipocyte size 
correlated positively with BMI. Pasarica et 
al. found that 41 diabetic subjects had a 
significantly higher mean SC adipocyte size 
and greater proportion of very large 
adipocytes than 192 BMI-matched non-
diabetic subjects (Pasarica et al., 2009). In 
contrast, no correlation was observed 
between SC adipocyte size and BMI in the 
diabetic subjects (Pasarica et al., 2009). 
 
These data raise the possibility that 
increased SC adipocyte size influences liver 
fat content independent of age, gender, 
obesity, fat distribution or PNPLA3 
genotype. The latter is of interest as, in 
addition to liver fat (Sookoian and Pirola, 
2011), genetic variation in PNPLA3 may 
also impact SC adipocyte size (Santoro et 
al., 2010).  
 
2.2.1.6.2.1. Methods for assessing adipocyte 
size 
 
Adipocyte size from adipose tissue biopsy 
is most commonly determined using one of 
three methods: collagenase digestion, 
osmium tetroxide fixation or histological 
analysis.  
 
The most commonly used method for 
determination of adipocyte size is 
collagenase digestion, developed by 
Rodbell, to separate mature adipocytes 
from the SVF (Rodbell, 1964). In short, 
adipose tissue is digested by collagenase 
and mature adipocytes are separated from 
the SVF by floatation in an aqueous 
solution. Adipocyte size is determined by 
calculating the mean size of 100 to 300 
adipocytes with a phase-contrast 
microscope. A limitation is that small 
adipocytes may not float as easily as the 
larger cells due to their lower lipid content 
(Ashwell et al., 1976), and adipocytes may 
break in unfixed tissue (Ashwell et al., 
1976); however, the use of adenosine in the 
solution has minimized the bias.  
 
Osmium tetroxide fixation and analysis 
using the Multisizer Counter was 
introduced by Hirsch (Hirsch and Gallian, 
1968). Osmium tetroxide fixes intracellular 
lipids and allows staining of very fragile 
cell types. In short, adipose tissue is 
digested by collagenase and thereafter 
fixed with osmium tetroxide, or 
simultaneously if collidine-HCl solution is 
used instead of collagenase for digestion. 
Adipocytes are analysed with a counter 
that measures cell size by fluctuation of 
electrical resistance. A wider distribution 
of adipocyte size may be analysed 
(Etherton et al., 1977). Even though very 
small adipocytes may be identified, a 
threshold value is often used to distinguish 
between mature adipocytes and artefacts, 
and multilobular adipocytes may rupture 
during fixation. This technique is slow and 
requires handling of osmium tetroxide, 
which is a hazardous chemical (Ashwell et 
al., 1976).  
 
Adipocyte size may also be estimated from 
histological slides. This is the only method 
for examining global tissue architecture, 
and immunostaining may be performed 
simultaneously. Fixation agents are known 
to cause significant cell shrinkage, and it 
must be assumed that cell distribution is 
uniform and that cells occur as perfect 
spheres that show their largest diameter 
(Ashwell et al., 1976). 
 
Collagenase digestion and osmium fixation 
seem to create similar mean values for 
adipocyte size while histological evaluation 
results in approximately 15% smaller mean 
values than the two other methods 
(Laforest et al., 2015).   
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2.2.1.6.3. Mechanisms of adipo-hepatic 
communication: adiponectin 
 
Adiponectin is a protein produced maily by 
adipocytes (Nigro et al., 2014) and its 
expression is primarily determined by 
adipocyte size and insulin sensitivity 
(Drolet et al., 2012). In the liver, 
adiponectin has insulin-sensitising, 
antifibrogenic, and anti-inflammatory 
properties by acting on hepatocytes, 
hepatic stellate cells, and hepatic 
macrophages (Kupffer cells), respectively 
(Polyzos et al., 2010). Adiponectin 
knockout mice show impaired insulin 
signalling in the liver (Yano et al., 2008) 
and have hepatic insulin resistance 
(Nawrocki et al., 2006). Moreover, 
adiponectin knockout mice develop more 
extensive liver fibrosis compared to wild-
type mice, whereas adenovirus-mediated 
overexpression of adiponectin ameliorates 
liver damage in wild-type mice (Kamada et 
al., 2003). In ob/ob mice, insulin 
resistance and liver fat can be significantly 
improved by overexpression of adiponectin 
in adipose tissue (Kim et al., 2007). 
 
In humans, an association between 
adiponectin deficiency and NAFLD has 
been shown in several studies (Bugianesi, 
Pagotto, et al., 2005; Koska et al., 2008; 
Targher et al., 2006). In the Dallas Heart 
Study (DHS), in which liver fat (1H-MRS) 
and serum adiponectin were measured in 
2215 subjects, adiponectin deficiency was 
associated with NAFLD independent of 
obesity (Turer et al., 2012). In a meta-
analysis of 27 studies comprising a total of 
1545 subjects with NAFLD and 698 
controls (Polyzos et al., 2011), healthy 
subjects had significantly higher serum 
adiponectin concentrations than those 
with NAFL, and the subjects with NASH 
had significantly lower serum adiponectin 
than the subjects with NAFL (Polyzos et 
al., 2011). Treatment with PPARγ agonists 
thiazolidinediones (TZDs), such as 
pioglitazone and rosiglitazone, increases 
serum adiponectin by 2- to 3-fold (Bajaj et 
al., 2004; Tiikkainen et al., 2004). 
Increase in serum adiponectin correlates 
closely with decrease in liver fat and with 
improvement of hepatic insulin resistance 
(Bajaj et al., 2004; Tiikkainen et al., 
2004). Adiponectin regulates ceramide 
metabolism by upregulating ceramidase, 
the enzyme that degrades ceramide to 
sphingosine, and adiponectin deficiency 
has also been shown to increase ceramide 
synthesis (Chavez and Summers, 2012). 
Indeed, adiponectin concentration 
correlates inversely with hepatic ceramide 
concentrations in the human liver 
(Luukkonen, Zhou, Sädevirta, et al., 2016).  
 
2.2.1.7. Insulin clearance and its impact on 
fasting insulin concentration 
 
Approximately 80% of endogenously 
secreted insulin and 50% of intravenously 
infused insulin is cleared by the liver 
(Ferrannini et al., 1983). Insulin clearance 
decreases in proportion to liver fat content, 
and insulin clearance and liver fat content 
are both independent determinants of the 
fasting insulin concentration (Kotronen, 
Vehkavaara, et al., 2007). In 80 non-
diabetic subjects whose liver fat content 
ranged from 0.4% to 41% as measured 
using 1H-MRS, liver fat content and insulin 
clearance accounted for 38% and 42% of 
the variation in fasting serum (fS)-insulin 
concentrations, respectively (Kotronen, 
Vehkavaara, et al., 2007). Both liver fat 
and insulin clearance were independent 
determinants of fS-insulin concentrations 
and together accounted for 53% of its 
variation. Increased liver fat is also 
associated with impaired insulin clearance 
in subjects with type 2 diabetes (Kotronen, 
Seppälä-Lindroos, et al., 2008).  
 
2.2.2. ‘Genetic NAFLD’ 
 
2.2.2.1. The PNPLA3 I148M variant 
 
In vitro studies and studies in 
experimental animals suggest two distinct 
mechanisms for the function of the 
PNPLA3 I148M variant. The gene variant 
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has been shown to disrupt 
intrahepatocellular hydrolysis of 
triglycerides, resulting in accumulation of 
triglycerides in hepatocytes (He et al., 
2010; Huang et al., 2011). The variant has 
also been shown to act as a 
lysophosphatidic acid-acyltransferase and 
activate triglyceride synthesis to a greater 
extent from long unsaturated FA 
containing coenzyme A than from 
saturated FA containing coenzyme A 
(Kumari et al., 2012). In vivo, the increase 
in liver fat in carriers of PNPLA3 I148M is 
due to polyunsaturated triglycerides, 
unlike in ‘Metabolic NAFLD’, in which 
saturated triglycerides and insulin 
resistance-inducing ceramides are 
increased (Luukkonen, Zhou, Sädevirta, et 
al., 2016).  
 
In 22 out of 24 studies, ‘PNPLA3 NAFLD’ 
is not associated with features of the MetS, 
such as hypertriglyceridemia, 
hyperglycaemia or low HDL cholesterol 
(Cox et al., 2011; Del Ben et al., 2014; 
Hyysalo et al., 2014; Kantartzis et al., 
2009; Kitamoto et al., 2013; Kotronen, 
Johansson, et al., 2009; Li et al., 2012; Lin 
et al., 2011; Musso et al., 2015; Park et al., 
2015; Petit et al., 2010; Romeo et al., 
2008; Romeo, Sentinelli, Cambuli, et al., 
2010; Romeo, Sentinelli, Dash, et al., 
2010; Scorletti et al., 2015; Sookoian et al., 
2009; Speliotes et al., 2011; Valenti, Alisi, 
et al., 2010;  Verrijken et al., 2013; 
Wagenknecht et al., 2011; Wang et al., 
2011; Xia, Ling, et al., 2016) or inflamed 
adipose tissue (Lallukka et al., 2013). In a 
study of morbidly obese subjects 
undergoing bariatric surgery, PNPLA3 
I148M variant was paradoxically 
associated with increased risk of type 2 
diabetes, but lower concentration of 
circulating triglycerides (Palmer et al., 
2012). In a study including 279 overweight 
or obese adolescents, the prevalence of 
MetS was higher in the homozygous 
carriers of the PNPLA3 I148M variant than 
in the non-carriers (9.2% vs. 5%, 
respectively, p<0.05 for comparison) 
(Mangge et al., 2015). Liver fat was not 
measured in these studies. There are no 
systematic reviews addressing the 
association of insulin resistance to 
‘PNPLA3 NAFLD’.  
 
2.2.2.2. The TM6SF2 E167K variant 
 
The exact molecular mechanism by which 
the TM6SF2 E167K variant increases the 
risk of NAFLD is still unclear. In vitro 
studies suggest that lipidation of VLDL 
particles is decreased (Smagris et al., 
2016), leading to impaired VLDL secretion 
and increased liver fat content 
(Mahdessian et al., 2014). Reducing 
Tm6sf2 transcripts in the mouse liver 
using recombinant adeno-associated viral 
vectors expressing short hairpin RNAs 
(Kozlitina et al., 2014) and knocking out 
TM6SF2 in mice (Smagris et al., 2016) 
causes steatosis. In the latter study, plasma 
VLDL-TG concentration decreased 
markedly (Smagris et al., 2016). In another 
study, inhibition of TM6SF2 by small 
interfering RNA also decreased the export 
of triglyceride-rich lipoproteins and lipid 
droplet content in human hepatoma cells 
(Huh7 and HepG2) (Mahdessian et al., 
2014).  
 
In vivo studies in humans have shown that 
carriers of the TM6SF2 E167K variant have 
a 2.1-fold higher risk of NAFLD, while 
lower circulating total and low-density 
lipoprotein (LDL) cholesterol, and 
triglyceride concentrations than the non-
carriers (Pirola and Sookoian, 2015). 
Carriers of the E167K variants seem to be 
protected against cardiovascular disease 
(Dongiovanni et al., 2015; Pirola and 
Sookoian, 2015). No systematic review on 
the association of insulin resistance and 
‘TM6SF6 NAFLD’ exists. 
 
2.2.2.3. The MBOAT7 rs641738 C>T variant 
 
Little is known about the function of the 
recently discovered MBOAT7 variant. 
MBOAT7 functions as an acyltransferase 
that catalyses acyl-chain remodelling of 
phosphatidylinositols (PIs). In vitro in 
  Review of the Literature 
	
  25   
mice, knockout of MBOAT7 affects 
concentrations of hepatic polyunsaturated 
PIs (Anderson et al., 2013). The MBOAT7 
rs641738 T allele was found to be 
associated with lower protein expression in 
the liver, and in changes in plasma PI 
species (decrease in PI(36:4) and PI(38:3), 
but an increase in PI(40:5)), but there was 
no association in other lipid classes 
(Mancina et al., 2016). Similar changes in 
polyunsaturated PIs were also found in the 
human liver lipidome in carriers of the 
MBOAT7 variant allele (Luukkonen, Zhou, 
Hyötyläinen, et al., 2016). 
 
In the only study to report serum lipid 
data, there was no difference in total, LDL 
or HDL cholesterol or in triglyceride 
concentration or incidence of type 2 
diabetes between carriers and non-carries 
of the T allele (Mancina et al., 2016). No 
studies have reported data on insulin 
resistance markers in ‘MBOAT7 NAFLD’.  
 
2.3. DIAGNOSIS OF NAFLD  
 
The gold standard for the diagnosis of 
NAFLD is histological examination of a 
liver biopsy. As performing a liver biopsy 
to all the patients with suspected NAFLD is 
not available in clinical practice and carries 
the risk of severe complications, non-
invasive methods for evaluation of hepatic 
steatosis have been introduced. Hepatic 
steatosis can be assessed quantitatively or 
qualitatively using different imaging 
methods, such as magnetic resonance 
imaging (MRI), 1H-MRS, ultrasound (US), 
and computed tomography (CT).  
 
As NAFLD predicts both complications 
and mortality on liver-related and 
metabolic causes, the definition of normal 
liver fat and the recognition of subjects 
with NAFLD is important. There are no 
systematic reviews of the definitions of 
normal liver fat content using different 
diagnostic methods and how they 
correspond to the liver histology.  
Different laboratory tests and scores using 
a combination of biochemical and 
anthropometric variables have also been 
introduced to evaluate the presence of 




A liver biopsy is the gold standard for 
diagnosis of NASH and for assessment of 
the degree of fibrosis (Rockey et al., 2009). 
Liver biopsy is most commonly performed 
percutaneously using US guidance, but can 
also be obtained transvenously from the 
jugular or femoral vein, or during 
laparoscopy or laparotomy (Rockey et al., 
2009). The most common complication of 
a percutaneous liver biopsy is pain, 
occurring in up to 84% of patients 
(Eisenberg et al., 2003). However, 
following a liver biopsy, more serious 
complications may ensue, most 
importantly intraperitoneal bleeding and 
even death (Piccinino et al., 1986). The 
mortality rate is less than 1 in every 10 000 
biopsies, and is usually related to 
haemorrhage (Myers et al., 2008; 
Piccinino et al., 1986). 
 
Steatosis, inflammation and ballooning of 
hepatocytes are characteristic for NASH. 
For research purposes, two algorithms are 
used for evaluating the severity of the 
disease rather than actually diagnosing 
NASH. The NAFLD Activitity Score (NAS 
Score) (Kleiner et al., 2005) takes into 
account steatosis, inflammation, 
ballooning and fibrosis. Steatosis is 
evaluated as the amount of steatotic 
hepatocytes, using a grading from 0 to 3 
(0: <5%; 1: 5%–33% 2: 34%–66%; 3: 
>67%), and also steatosis location from 0 
to 3 (0:  zone 3; 1: zone 1; 2: azonal; 3: 
paracinar). Lobular inflammation is 
graded from 0 to 3 (0: none; 1: <2; 2: 2–4; 
3: >4), chronic portal inflammation from 0 
to 2 (0: none; 1: mild; 2: > mild) and 
ballooning from 0 to 2 (0: none; 1: few; 2: 
many). Fibrosis is scored from 0 to 3 (stage 
0: none; 1a–c: 1a or 1b sinusoidal zone 3 or 
1c portal fibrosis; 2: perisinusoidal and 
Review of the Literature 
	
26   
periportal fibrosis without bridging; 3: 
bridging fibrosis; and 4: cirrhosis). Even 
though some studies use a NAS score of ≥5 
as a surrogate for histologic diagnosis of 
NASH, it has been shown in a study of 976 
biopsies that of those with definite NASH, 
only 75% had a NAS score of ≥5 (Brunt et 
al., 2011). 
 
A newer, simpler score, the SAF score 
(Bedossa et al., 2012; Bedossa et al., 2014) 
was introduced in 2014. The SAF score is 
determined from three main histological 
lesions: steatosis, activity and fibrosis. The 
steatosis score (S, from S0 to S3) indicates 
the quantities of macrovesicular, not 
microvesicular, lipid droplets as in the NAS 
score. The activity grade (A, from A0 to A4) 
is the sum of scores of hepatocyte 
ballooning (0-2, where 0: normal 
hepatocytes with cuboidal shape and pink 
eosinophilic cytoplasm; 1: the presence of 
clusters of hepatocytes with a rounded 
shape and pale cytoplasm; 2: the same as 1 
but with some enlarged hepatocytes) and 
lobular inflammation (0–2, where lobular 
inflammation is defined as the focus of two 
or more inflammatory cells within a lobule, 
and the foci are counted at 20 x 
magnification; 0: none; 1: ≤2 foci per 20 x; 
2: >2 foci per 20 x ), as A0 (A=0) is no 
activity, A1 (A=1) is mild activity, A2 (A=2) 
is moderate activity and A3 (A≥3) is severe 
activity. The stage of fibrosis (F) is defined 
as in the NAS score (F0–F4). NAFLD is 
defined as presence of steatosis in >5% of 
hepatocytes and NASH by the presence, in 
addition, of hepatocellular ballooning of 
any degree and lobular inflammatory 
infiltrates of any amount.  
 
Liver biopsy represents approximately 
1/50000th to 1/65000th of the liver, and is 
therefore susceptible to sampling error. A 
study on 51 paired liver biopsies from 
patients with NAFLD demonstrated that in 
24% of cases, ballooning necrosis would 
have been missed with only one biopsy, 
and the fibrosis was understaged in 35% of 
the cases (Ratziu et al., 2005). In a study of 
41 paired biopsies from subjects with 
NAFLD, the agreement of the steatosis 
grade between the right and left lobe of 
liver was excellent (κ=0.88), of fibrosis the 
agreement moderate (κ=0.51), but only 
modest for lobular inflammation (κ=0.32) 
and hepatocyte ballooning (κ=0.20) 
(Merriman et al., 2006). Inter-observer 
and intra-observer variability between 
pathologists is considerable especially for 
lower fibrosis grades (Bedossa et al., 2014). 
Grading of steatosis and staging of fibrosis 
is relatively reliable in terms of inter-
observer and intra-observer variability, but 
worse for lobular inflammation and 
ballooning (Ratziu et al., 2005; Merriman 
et al., 2006). Overall inter-observer and 
intra-observer agreement scores for the 
diagnosis of NASH are moderate to high at 
0.66–0.90 and 0.61–0.62, respectively 
(Ratziu et al., 2005; Merriman et al., 
2006). 
 
2.3.2. Imaging methods 
 
2.3.2.1. Liver fat content 
 
2.3.2.1.1. Proton magnetic resonance 
spectroscopy (1H-MRS) 
 
1H-MRS is an MRI-based method that 
enables sampling of a much larger volume 
fraction of the liver compared to a biopsy, 
typically a single voxel of 2 x 2 x 2 cm3 or 3 
x 3 x 3 cm3 (Longo et al., 1993; Szczepaniak 
et al., 1999). 1H spectra of liver tissue show 
two dominant signals that reflect liver fat 
content: peaks of water, and peaks of the 
methylene and methyl protons of 
triglycerides (Festi et al., 2013). The 
resonances from the methylene and methyl 
protons of triglyceride acyl chains appear 
between 1.0 and 1.6 ppm (Szczepaniak et 
al., 1999). The fat-signal fraction 
represents the ratio of the signal from the 
protons of triglycerides to the sum of the 
signals from protons of both free water and 
triglycerides (Festi et al., 2013). Total 
hepatic triglyceride content is then 
calculated by summing the individual lipid 
peaks in the 0.5 to 3.0 ppm region of the 
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MR spectrum to obtain the total lipid peak 
area and dividing this with the sum of the 
total lipid and the water resonance peaks 
in 3.0 to 5.5 ppm region (Szczepaniak et 
al., 2005). 1H-MRS is highly reproducible 
(Cowin et al., 2008; Machann et al., 2006; 
Szczepaniak et al., 1999), and has become 
the gold standard for quantifying steatosis 
as it is the most accurate method (Bohte et 
al., 2011). Patients are not exposed to 
excessive radiation, as they are during CT 
scanning. However, the method is 
expensive, requires technical expertise for 
performance and is not readily available in 
clinical practice. 
 
2.3.2.1.2. Magnetic resonance imaging 
(MRI) 
 
Several MR imaging techniques are 
available. The most widely used is called 
in-phase (IP) and opposed-phase (OP) 
imaging, that is also known as chemical 
shift imaging Dixon technique (Cassidy et 
al., 2009; Dixon, 1984; Fishbein and 
Stevens, 2001; Fishbein et al., 1997; Rofsky 
et al., 1996). This technique is universally 
available in all modern clinical 1.5 and 3 T 
systems and is included in most clinical 
abdominal MR examinations (Kinner et 
al., 2016). In this method, two sets of 
images are captured: the IP image in which 
the water and fat signals are approximately 
in-phase, and the OP image where the two 
signals are in opposed-phase. The IP image 
represents the sum of water and fat signals 
of the liver and the OP image their 
difference (Kinner et al., 2016). In a non-
steatotic liver, where no fat is present, the 
liver signal in OP and IP is nearly the 
same, as only the water contributes to the 
liver signal. With increasing degree of 
steatosis, the liver parenchyma becomes 
darker on the OP images. The liver signal 
fat fraction is defined as the proportion of 
the fat signal divided by the total (water + 
fat) signal. 
 
More recently, advanced MRI techniques 
(magnitude- and complex data-based) 
have been developed that eliminate the 
biases seen with conventional MRI and 
estimate the proton density fat fraction 
(PDFF), defined as the fraction of mobile 
protons of triglycerides relative to those 
that of the properties of water (Bydder et 
al., 2008; Hines et al., 2011; Meisamy et 
al., 2011; Yokoo et al., 2009). MRI-PDFF 
provides an estimation of liver fat content 
from all the segments of the liver 
(Bonekamp et al., 2014). While technical 
details vary, the common strategy is to 
acquire imaging data at multiple different 
echo times and perform time-domain 
analysis (curve fitting) to estimate the 
signals originating from triglyceride and 
water. The MRI-PDFF correlates closely 
with histological liver fat content 
(Bonekamp et al., 2014; Hines et al., 2011; 
Noureddin et al. 2013).  
 
2.3.2.1.3. Computed tomography (CT) 
 
CT provides an accurate and reliable 
visualisation of the entire liver, unlike 1H-
MRS and liver biopsy. Hepatic steatosis 
can be best evaluated in non-enhanced CT 
images (Siegelman and Rosen, 2001). 
Tissue fat deposition lowers attenuation, 
making fatty areas less dense and appear 
darker than the non-fatty tissues, such as 
the spleen (Piekarski et al., 1980). 
Steatosis of the liver can be assessed by the 
absolute measurement of attenuation 
values in Hounsfield units (HU), 
comparing attenuation of the liver 
parenchyma to that of the spleen or 
calculating the spleen-to-liver attenuation 
ratio (Schwenzer et al., 2009). The main 
advantage of CT imaging is its wide 
availability and relatively moderate cost, 
but radiation exposure prevents use of CT 
for screening purposes (Fierbinteanu-
Braticevici, 2010). 
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2.3.2.1.4. Ultrasound (US) 
 
US is a widely available tool that is less 
expensive than MRI, 1H-MRS or CT (EASL 
et al., 2016). Hepatic steatosis appears as a 
diffuse increase in parenchymal brightness 
and echogenicity in US images, and is 
often compared to hypoechogenity of the 
kidney cortex. A disadvantage of US 
imaging is its poor sensitivity, especially in 
obese subjects. In a prospective study 
comprising 187 obese subjects who were to 
undergo US imaging before bariatric 
surgery, the sensitivity of US for 
diagnosing biopsy-proven steatosis was 
49% (Mottin et al., 2004). In a study of 
100 consecutive living liver donors, the 
sensitivity of US to detect 5–10%, 10–19%, 
20–30% and >30% steatosis was 12%, 
55%, 72%, and 80% (Ryan et al., 2002). 
Another weakness of ultrasound is its 
operator-dependency. Three independent, 
experienced radiologists evaluated liver 
steatosis in 168 patients, and the 
examination was repeated after one 
month. The mean inter- and intra-observer 
agreement rates for the presence of 
increased liver fat were 72% and 76% 
(Strauss et al., 2012). Intra-observer 
agreement for the severity of fatty liver 
ranged from 55% to 68% (Strauss et al., 
2012). 
 
2.3.2.2. Assessment of fibrosis 
 
Transient elastography (TE) with 
Fibroscan® (Echosens, Paris, France) 
(Sandrin et al., 2003) and acoustic 
radiation force impulse (ARFI) 
elastography using Siemens AcusonS2000 
(Siemens AG, Erlangen, Germany) are US-
based techniques for non-invasive 
assessment of liver stiffness, which is a 
surrogate marker for liver fibrosis (Bota et 
al., 2013). A meta-analysis consisting of 13 
studies and 1163 subjects who had 
undergone a liver biopsy concluded that 
the two methods performed equally well in 
detection of significant fibrosis and 
cirrhosis (Bota et al., 2013). For the 
detection of significant fibrosis (F≥2), the 
sensitivity was 74% and specificity 83% for 
ARFI, while for TE the sensitivity was 78% 
and specificity 84%. For the diagnosis of 
cirrhosis, the sensitivity was 87% and 
specificity 87% for ARFI, and, respectively, 
89% and 87% for TE.  
 
Magnetic resonance elastography (MRE) is 
a non-invasive MRI-based technique for 
quantitative assessment of increased 
stiffness of the liver parenchyma 
(Venkatesh et al., 2013; Yin et al., 2007). 
MRE may be performed simultaneously 
with MRI-PDFF. A meta-analysis of 11 
MRE studies comprising 982 patients 
found that area under the receiver 
operating characteristics curve (AUROCs) 
for MRE staging fibrosis were 0.94, 0.97, 
0.96 and 0.97 for F1–F4, respectively, and 
in 15 ARFI studies comprising 2128 
patients 0.82, 0.85, 0.94 and 0.94 for F1–
F4, respectively (Guo et al., 2014). The two 
studies comparing MRE and TE in 
differentiation of significant fibrosis 
concluded that MRE is significantly more 
accurate than TE (Imajo et al., 2016; Park 
et al., 2017). 
 
2.3.3. Circulating biochemical markers 
 
In ‘Metabolic NAFLD’, liver fat closely 
correlates with direct and indirect 
measures of insulin resistance, liver 
enzymes and other markers. 
 
2.3.3.1. Measures of insulin resistance  
 
2.3.3.1.1. Fasting insulin  
 
In 271 non-diabetic subjects studied in our 
laboratory, the correlation coefficient 
between liver fat measured by 1H-MRS and 
fS-insulin concentration was 0.61 
(p<0.001). The relationship between liver 
fat and fS-insulin remained significant 
even after adjustment for age, gender and 
BMI (Kotronen, Westerbacka, et al., 2007). 
No difference in regression lines or slopes 
was found between genders. The 
correlation coefficient was better than that 
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between liver fat and liver enzymes such as 
alanine aminotransferase (ALT) (r=0.39, 
p<0.0001 for women and r=0.33, 
p<0.0001 in men, significant difference in 
intercepts) and aspartate aminotransferase 
(AST) (r=0.27, p=0.0005 for women and 
r=0.31, p=0.0012 in men, significant 
difference in intercepts) (Kotronen, 
Westerbacka, et al., 2007). In subsequent 
studies, a similar close relationship 
between liver fat measured with 1H-MRS 
and fasting insulin has been found. These 
studies included 42 non-diabetic 
Americans (r=0.60, p<0.001) (Korenblat 
et al., 2008), 43 diabetic Americans 
(r=0.48, p<0.05) (Gastaldelli et al., 2007), 
17 Australians (r=0.50, p<0.05) (Chan et 
al., 2006), 47 non-diabetic Chinese 
(r=0.41, p<0.05) (Bian et al., 2011), 216 
type 2 diabetic Americans (r=0.31; 
p<0.001) and 136 non-diabetic Americans 
(r=0.37; p<0.001) (Bril et al., 2017).  
 
When diabetes develops, insulin secretion 
starts to decrease relative to plasma 
glucose, which complicates its use as a 
surrogate for liver fat in the subjects 
(DeFronzo et al., 1992; DeFronzo, 2009; 
Gastaldelli, 2011; Lillioja et al., 1988;). 
Another problem is that insulin analogues 
are not detected with modern insulin 
assays (Heurtault et al., 2014). As type 2 
diabetic patients’ requirements for insulin 
correlate with their insulin resistance 
(Ryysy et al., 2000), it would thus be 
desirable to measure all the insulins. 
 
The intra- and inter-assay coefficient of 
variation (CV) of a single insulin assay and 
variation between different insulin assays 
should be known (Manley et al., 2007). In 
1996, the American Diabetes Association 
task force on standardisation of insulin 
assays concluded that there is wide inter-
assay variation in insulin measurements 
(Robbins et al., 1996). Manley et al. have 
compared 11 insulin assays and showed 
that insulin concentrations vary over 2-fold 
depending on the assay used (Manley et 
al., 2007). Assay specificity, calibration 
procedures, specimen types, assay 
performance, and conversion factors may 
contribute to inter-assay variation (Manley 
et al., 2007). Regarding conversion 
between units from mU/l to pmol/l, the 
conversion factor varies between 6.0 to 
7.46 depending on the assay used, and is 
yet another source of variation (Manley et 
al., 2007). Proinsulin cross-reacts with 
insulin antibodies in some assays, although 
proinsulin concentrations do not usually 
exceed 10% of the total insulin measured 
(Manley et al., 2007). Specific assays are 





The homeostasis model assessment of 
insulin resistance (HOMA-IR) is calculated 
as the product of fasting glucose (in 
mmol/l) and insulin (in mU/l) 
concentrations divided by 22.5 (Matthews 
et al., 1985). As insulin resistance develops 
in the liver, glucose concentrations 
increase because insulin fails to suppress 
hepatic glucose production in the normal 
manner (Seppälä-Lindroos et al., 2002). 
This stimulates beta cells to increase 
insulin secretion resulting in a 
combination of hyperglycemia and 
hyperinsulinemia. This combination 
increases the product of fasting glucose 
and insulin, i.e. HOMA-IR. 
 
HOMA-IR provides a good surrogate 
marker of hepatic insulin resistance as long 
as glucose tolerance remains non-diabetic. 
After the development of diabetes, insulin 
secretion starts to decrease relative to 
plasma glucose (DeFronzo et al., 1992; 
DeFronzo, 2009; Gastaldelli, 2011; Lillioja 
et al., 1988;). Under such conditions, 
HOMA-IR is no longer a reliable marker of 
insulin resistance. If there is no 
endogenous insulin secretion left (type 1 
diabetes), insulin measurement does not 
reflect insulin resistance, and direct 
methods such as the euglycemic insulin 
clamp technique are more appropriate for 
assessment of insulin sensitivity (Donga et 
al., 2015).  
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As discussed earlier, once the liver 
becomes fatty, both insulin sensitivity and 
clearance decrease. This implies that 
HOMA-IR might overestimate insulin 
resistance in individuals in whom insulin 
resistance is associated with a fatty liver 
(Kotronen, Vehkavaara, et al., 2007). 
 
2.3.3.1.2.1. Reference value for HOMA-IR 
 
A recent joint European Practice guideline 
on NAFLD by the European Association for 
the Study of the Liver (EASL), the 
European Association for the Study of 
Diabetes (EASD) and the European 
Association for the Study of Obesity 
(EASO) (EASL et al., 2016) stated: 
‘HOMA-IR provides a surrogate estimate 
of insulin resistance in persons without 
diabetes and can therefore be 
recommended provided proper reference 
values have been established’. 
 
Reference intervals are usually defined 
according to the recommendations of the 
International Federation of Clinical 
Chemistry and Laboratory Medicine 
(IFCC) (Solberg, 1987). A reference 
population is a group of reference 
individuals who are healthy people 
fulfilling pre-defined criteria. A reference 
value is measured from each reference 
individual by an appropriate method, and 
the statistical distribution of the reference 
values is then used to produce reference 
intervals. The reference interval is the area 
between and including both the lower and 
upper reference limits.  
 
Reference intervals are usually defined in a 
population-based sample of age and 
gender-matched individuals as the mean 
±2 standard deviation (SD) for variables 
with a Gaussian distribution, or as the 
central 95% reference interval (90% 
confidence interval [CI]) for variables that 
are non-normally distributed (Gräsbeck 
and Alström, 1981; Horn and Pesce, 2003). 
However, if the lower 2.5th percentile is not 
clinically relevant as in the case of HOMA-
IR, a one-sided upper limit, the 95th 
percentile, may be used as the reference 
value (Horn and Pesce, 2003). 
 
Regarding a reference value for HOMA-IR, 
the problem with this definition is that 
health then becomes dependent on the 
underlying population, as obesity is highly 
prevalent and perhaps the single most 
important cause of variation in insulin 
sensitivity. Thus for HOMA-IR, it would 
seem wiser to use reference values which 
are based on a study of only healthy 
subjects, although the definition of 
‘healthy’ may also vary (Velho et al., 2010). 
Controllable pre-analytical causes (the 
specimen collection technique, posture, 
fasting/postprandial, rest/exercise, drugs, 
stress, circadian variation) and non-
controllable pre-analytical causes (age, 
gender, ethnicity) of variation should also 
be considered in defining reference value 
for HOMA-IR. Also, as discussed earlier, 
the inter-assay variation in insulin 
measurements must be taken into account 
when defining a reference value for 
HOMA-IR.  
 
Three previous studies have been 
performed in ‘healthy’ and non-obese 
subjects (BMI <25 kg/m2) comprising 161 
Japanese subjects, 161 Italian subjects and 
312 Brazilian subjects (Bonora et al., 1998; 
Geloneze et al., 2006; Nakai et al., 2002). 
In the Japanese study, the 90th percentile 
of HOMA-IR was 1.7 (Nakai et al., 2002). 
In the Italian study, the 80th percentile of 
HOMA-IR was 2.77 (Bonora et al., 1998). 
In the Brazilian study, the 90th percentile 
was equally high, 2.71. 
 
2.3.3.1.2.2. HOMA-IR in NAFLD 
 
By definition, a number of studies have 
shown that subjects with ‘Metabolic 
NAFLD’ have higher HOMA-IR than 
subjects without NAFLD (Adams et al., 
2009; Angulo et al., 2004; Brunt et al., 
2011; Chalasani et al., 2003; Marchesini et 
al., 1999; Targher et al., 2006). HOMA-IR 
has a strong positive correlation with liver 
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fat content (Adiels et al., 2007; Fedchuk et 
al., 2014; Finucane et al., 2013). Two 
earlier studies have defined a cut-off for 
HOMA-IR in the diagnosis of NAFLD. A 
study by Salgado et al. included 116 
Brazilian subjects with NAFLD diagnosed 
by US (51%) or biopsy (49%) and in 
addition 88 healthy subjects (Salgado et 
al., 2010). In receiver operating 
characteristics (ROC) curve analysis, a 
HOMA-IR of 2.0 with an AUROC of 0.84 
(95% CI 0.78–0.90) was the best for 
distinguishing between NAFLD and non-
NAFLD subjects. The sensitivity was 85% 
and specificity 83%. A study by Perez et al. 
included 263 Columbian men, of whom 
27% had NAFLD as diagnosed by US 
(Perez et al., 2011). The best cut-off for 
NAFLD was a HOMA-IR of 1.74 with an 
AUROC of 0.78, sensitivity of 74% and 
specificity of 73% (Perez et al., 2011). 
 
It is unknown how HOMA-IR relates to the 
normal amount of liver fat as defined in 
the DHS, and whether this definition 
reflects what normal liver fat is in other 
centers using 1H-MRS. Moreover, the 
impact of PNPLA3 I148M variant on 
reference values for HOMA-IR has not 
been studied.  
 
2.3.3.1.3. Phosphorylated IGFBP-1 (pIGFBP-
1) 
Insulin-like growth factor binding protein-1 
(IGFBP-1) is one of six IGFBPs which 
regulate the bioavailability of insulin-like 
growth factor-1 (IGF-1) by binding to it 
(Firth and Baxter, 2002). In non-pregnant 
adults, the liver is the exclusive site of 
production of IGFBP-1 (Brismar et al., 
1994). Hepatocytes produce primarily 
phosphorylated IGFBP-1 (pIGFBP-1), 
which has a 6-fold higher affinity for IGF-1 
than after dephosphorylation (Jones et al., 
1991). In circulation, pGFBP-1 is also the 
main form of IGFBP-1 (Jones et al., 1991), 
but a small amount of IGFBP-1 that is not 
phosphorylated is also found in the 
circulation (Jones et al., 1991). 
 
Insulin is the main regulator of serum 
IGFBP-1 in vivo (Suikkari et al., 1988). It 
acutely lowers IGFBP-1 concentrations 
(Suikkari et al., 1988). Insulin sensitivity 
also regulates serum IGFBP-1 
concentrations (Kotronen, Lewitt, et al., 
2008). Fasting IGFBP-1 is markedly lower 
in subjects with a fatty liver and hepatic 
insulin resistance than in subjects with fatty 
liver and normal hepatic insulin sensitivity 
(Kotronen, Lewitt, et al., 2008). 
 
Phosphorylated but no other forms of 
IGFPB-1 have been suggested to be 
associated with macrovascular 
complications of type 2 diabetes (Heald et 
al., 2002). Serum pIGFBP-1 may also 
correlate better with cardiovascular risk 
factors than lesser-phosphorylated IGFBP-1 
(Borai, Livingstone, Ghayour-Mobarhan, et 
al., 2010). These data provide a rationale 
for measuring specifically pIGFBP-1 rather 
than IGFBP-1 as a marker of liver fat 
content and associated metabolic 
abnormalities. 
 
As previously discussed, insulin assays are 
not well standardised and the 
concentrations may vary 2-fold when the 
same sample is measured using a different 
assay (Manley et al., 2007). Earlier studies 
have used radioimmunoassay (RIA) to 
measure IGFBP-1. Phosphorylation status 
alters the antigenicity of IGFBP-1 
(Westwood et al., 1994) and therefore 
immunoassays may grossly underestimate 
changes in IGFBP-1 concentrations. 
However, an assay measuring pIGFBP-1 
utilising antibodies and kits developed by 
one laboratory, Medix Biochemica 
(Kauniainen, Finland) (Rahkonen et al., 
2009; Riboni et al., 2011), can avoid 
problems of standardisation between 
laboratories. 
 
Previously, low fS-IGFBP-1 concentrations 
have been associated with NAFLD in 
studies comprising 142 Japanese subjects 
(Wasada et al., 2008), 48 Italian women 
(Savastano et al., 2011), and 49 African 
American and 77 Latino adolescents 
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(Alderete et al., 2011). Liver fat content has 
been shown to correlate inversely with fS-
IGFBP-1 in two studies comprising 48 
subjects (Kotronen, Lewitt, et al., 2008) 
and 113 subjects (Mofrad et al., 2003). 
There is, however, no data on the 
relationship between fS-pIGFBP-1 and 
liver fat content or data examining whether 
the measurement of fS-pIGFBP-1 helps in 
the prediction of liver fat content 
compared to routinely available predictive 
markers.  
 
2.3.3.2. Liver enzymes 
 
The liver enzymes AST, ALT and gamma-
glutamyltransferase (GGT) are routinely 
used surrogates of hepatocellular injury. 
ALT mostly originates from hepatocytes, 
while AST is also found in the heart and 
skeletal muscle, and GGT also in biliary 
epithelial cells and extrahepatic cells such 
as in the pancreas and renal tubules 
(Giannini, 2005). ALT is thus the most 
liver-specific of the enzymes, as increases 
in AST or GGT may also reflect 
extrahepatic pathology (Pratt and Kaplan, 
2000). Increased serum GGT activity has 
also been used in clinical practice as a 
marker of excessive alcohol intake, 
especially if GGT is twice above normal in 
patients with an AST/ALT-ratio of at least 
2:1 (Whitfield, 2008). In a Finnish 
population-based study including 2766 
subjects, GGT concentrations were 
significantly higher in subjects with 
alcoholic fatty liver disease than with 
NAFLD, but no difference was observed in 
the AST/ALT-ratio between the two liver 
diseases (Kotronen et al., 2010). NAFLD is 
the most common cause of elevation in 
these liver enzymes both in the United 
States (41% of increased ALT or 34% of 
increased AST due to NAFLD) (Lazo et al., 
2013), and in Finland (75% of increased 
ALT due to NAFLD) (Kotronen et al., 
2010).  
 
Liver fat positively correlates with serum 
ALT, AST and GGT concentrations in men 
and women (Westerbacka et al., 2004). 
The intercepts but not the slopes of the 
regression lines in the correlation between 
serum ALT and liver fat content differ 
between men and women (Westerbacka et 
al., 2004). This is in line with a reference 
range of ALT lower for women than for 
men, probably reflecting the gender 
difference in liver size. Recently in Finland, 
many hospital districts adopted lower 
reference values for serum ALT, i.e., 50 U/l 
in men and 35 U/l in women, which were 
based on values from normal weight 
abstainers (Danielsson 2014; Niemelä and 
Danielsson, 2015). 
 
Serum ALT is a poor marker of NAFLD. In 
a cohort of 222 subjects with biopsy-
proven NAFLD, 23% of subjects had 
normal ALT levels, and 38% of patients 
with normal ALT levels had NASH or 
advanced fibrosis (Verma et al., 2013). 
Despite normal ALT and AST levels, 56% 
of overweight or obese patients with type 2 
diabetes had NAFLD (Portillo Sanchez et 
al., 2015). According to a population-based 
study, up to 80% of subjects with NAFLD 
may remain undiagnosed if the diagnosis 
relies only on elevated liver enzymes 
(Browning et al., 2004).  
 
2.3.3.3. Scores  
 
Various combinations of biochemical and 
anthropometric measurements have been 
proposed as helpful in identifying patients 
with NAFLD. 
 
The Fatty Liver Index (FLI) was created on 
the basis of 216 Italian subjects with 
NAFLD and 280 without NAFLD 
diagnosed by US. The model included 
waist circumference, BMI, triglycerides 
and GGT (Bedogni et al., 2006), and had 
an AUROC of 0.84 (95% CI 0.81–0.87). 
The sensitivity of a low cut-off to rule out 
NAFLD was 87%, and the specificity of a 
high cut-off to diagnose NAFLD was 86%. 
The FLI has been validated in 336 British 
subjects (1H-MRS) (Cuthbertson et al., 
2014), 2652 Dutch subjects (US) (Koehler 
et al., 2013), 3548 Chinese subjects (US) 
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(Xia, Yki-Järvinen, et al., 2016), 324 
French subjects (liver biopsy) (Fedchuk et 
al., 2014) and 92 German subjects (1H-
MRS) (Kahl et al., 2014). The AUROC of 
FLI was 0.79 (25–75% 0.74–0.84) in the 
British study, 0.81 (95% CI 0.79–0.82) in 
the Dutch study, 0.76 (95% CI 0.75–0.78) 
in the Chinese study and 0.83 (95% CI 
0.72–0.91) in the French study and 0.72 
(95% CI 0.59–0.85) in the German study. 
 
The Hepatic Steatosis Index (HSI) was 
created on the basis of 5360 Korean 
subjects and validated in 5364 Korean 
subjects (Lee et al., 2010). All subjects 
underwent US to diagnose NAFLD, and 
2680 subjects of both cohorts had NAFLD. 
The HSI score included ALT/AST ratio, 
BMI, gender and diagnosis of diabetes. The 
AUROC for the model was 0.82 (95% CI 
0.80–0.83). The sensitivity of the low-cut 
off for ruling out NAFLD was 90.4% and 
the specificity of the upper cut-off for 
diagnosing NAFLD was 92.4%. The HSI 
has been validated in 3548 Chinese 
subjects (US) (Xia, Yki-Järvinen, et al., 
2016), 324 French subjects (liver biopsy) 
(Fedchuk et al., 2014) and 92 German 
subjects (1H-MRS) (Kahl et al., 2014). The 
AUROC of the HSI to diagnose NAFLD was 
0.77 (95% CI 0.75–0.78) in the Chinese 
study, 0.81 (95% CI 0.72–0.88) in the 
French study, 0.79 (95% CI 0.68–0.90) in 
the German study.  
 
Our group has previously developed a 
score for diagnosing NAFLD (the NAFLD 
Liver Fat Score) and an equation for 
estimating the amount of liver fat (NAFLD 
Liver Fat Equation) (Kotronen, Peltonen, 
et al., 2009). These data were based on a 
study of 470 subjects who had undergone 
1H-MRS for measurement of liver 
fatcontent (313 subjects as a discovery and 
157 subjects as a validation cohort) 
(Kotronen, Peltonen, et al., 2009). Both 
scores included diagnosis of MetS and type 
2 diabetes, fS-Insulin, AST and the 
AST/ALT ratio. The AUROC for the 
NAFLD Liver Fat Score was 0.88 (95% CI 
0.84–0.92) with a sensitivity of the model 
was 86% and specificity of 71%. The 
correlation between measured liver fat 
content and liver fat content calculated 
from the NAFLD liver fat equation was 
r=0.70, p<0.001. The NAFLD Liver fat 
score has later been validated in 3548 
Chinese subjects (US) (Xia, Yki-Järvinen, 
et al., 2016), 324 French subjects (liver 
biopsy) (Fedchuk et al., 2014) and 92 
German subjects (1H-MRS) (Kahl et al., 
2014). The AUROC of the NAFLD Liver Fat 
Score to correctly diagnose NAFLD was 
0.78 (95% CI 0.72–0.77) in the Chinese 
study, 0.80 (0.69–0.88) in the French 
study, and 0.70 (0.53–0.87) in the German 
study. In the German study, the NAFLD 
Liver Fat Equation correlated with hepatic 
fat content (r=0.42, p<0.001) but the ratio 
of observed and predicted hepatic fat 
content ranged from 0.02 to 12.2 (Kahl et 
al., 2014). 




3 AIMS OF THE STUDY 
 
The aims of the study were: 
 
i. to determine whether SC adipocyte size is associated with liver fat content 
independent of other factors such as age, gender, obesity, adipose tissue distribution 
and PNPLA3 genotype (study I); 
 
ii. to systematically review definitions of normal liver fat using different diagnostic 
methods and how the definitions correspond to liver histology (study II); 
 
iii. to systematically review whether there is a difference in insulin sensitivity between 
carriers and non-carriers of the PNPLA3 I148M variant, and carriers and non-carriers 
of the TM6SF2 E167K variant (study II); 
 
iv. to determine reference values for HOMA-IR in two population-based cohorts and the 
inter-laboratory variation of HOMA-IR measurements in seven European laboratories 
(study III); 
 
v. to define the HOMA-IR that best distinguishes between NAFLD and corresponds 
normal liver fat content, as quantified by 1H-MRS (study III); and 
 
vi. to determine whether pIGFBP-1 helps in the prediction of liver fat content in NAFLD 
compared to routinely available clinical and biochemical parameters (study IV).	
 




4 SUBJECTS AND 
METHODS  
 
4.1. SUBJECTS AND STUDY DESIGNS 
 
For studies I, III (the ‘Liver Fat Cohort’) 
and IV, the study subjects were recruited 
for metabolic studies between May 2001 
and October 2014 by newspaper 
advertisements, by contacting colleagues 
and occupational health services, or 
amongst subjects referred to the 
Department of Gastroenterology because 
of chronically elevated serum 
transaminase concentrations. Inclusion 
criteria were i) age 18 to 75 years, ii) no 
known acute or chronic disease other than 
obesity, type 2 diabetes, hypertension, 
hypercholesterolemia or NAFLD based on 
medical history, physical examination and 
standard laboratory tests (blood count, 
creatinine, electrolyte concentrations and 
electrocardiogram), iii) no pregnancy or 
lactation, iv) no evidence of pre-existing 
liver conditions other than NAFLD (e.g. 
autoimmune, viral or drug-induced liver 
disease) or a history of use of toxins or 
drugs associated with liver steatosis, 
antihypertensives possibly influencing 
glucose metabolism or TZDs, v) no 
excessive use of alcohol (over 20 g/day for 
women and 30 g/day for men). Study 
physicians assessed alcohol intake by using 
the same questionnaire addressing the 
quantity of different alcoholic drinks 
consumed during an average week. The 
study protocols were approved by the 
Ethics committee of Helsinki University 
Central Hospital and written informed 
consent was obtained from all study 
subjects.  
 
4.1.1. Adipocyte size in NAFLD 
 
Non-diabetic study subjects (n=119) 
participated in a metabolic study. The 
subjects were studied after an overnight 
fast. Body composition was measured as 
detailed below in section 4.2.4. Blood was 
drawn for measurement of complete blood 
count, serum total cholesterol, HDL and 
LDL cholesterol, triglyceride and plasma 
glucose concentration, and glycated 
haemoglobin A1c (HbA1c), serum insulin 
and C-peptide, ALT and AST 
concentrations. Blood samples were also 
obtained for genotyping PNPLA3 at 
rs738409 as described below in section 
4.2.6. Thereafter, a biopsy of abdominal 
subcutaneous adipose tissue was taken 
under local anaesthesia with 1% lidocaine 
by a needle aspiration (Yki-Järvinen et al., 
1986). In addition, on another occasion 
liver fat was measured with 1H-MRS, and 
abdominal SC and IA adipose tissue 
volumes were determined with MRI. Data 
on these subjects has been reported before 
(Kotronen, Peltonen, et al., 2009). 
 
4.1.2. Definition of normal liver fat and 
insulin sensitivity in ‘Genetic NAFLD’ 
 
A systematic review was performed on two 
topics: i) definitions of normal liver fat 
using 1H-MRS, MRI, US and CT, and ii) 
comparison of insulin sensitivity in 
carriers and non-carriers of the PNPLA3 
I148M variant, and the carriers and non-
carriers of the TM6SF2 E162K variant. 
 
4.1.3. Reference values for HOMA-IR and an 
optimal cut-off for NAFLD 
 
For determination of reference values for 
HOMA-IR, we studied non-pregnant 
adults in two population-based cohorts, 
the National FINRISK 2007 study 
conducted by the National Institute for 
Health and Welfare in Finland (Vartiainen 
et al., 2010) and the Programme for 
Prevention of Type 2 Diabetes in Finland 
(FIN-D2D) (Saaristo et al., 2007). Health 
was defined using the same criteria as in 
the population-based DHS (Szczepaniak et 
al., 2005): i) alcohol use less than 30 g/day 
in men and less than 20 g/day in women, 
ii) non-diabetic based on history and




normal fP-glucose (<6.1 mmol/l), iii) non-
obese (BMI <25 kg/m2), and iv) no clinical 
or biochemical evidence of other liver 
disease or metabolic syndrome as defined 
by history and biochemical examinations 
(vide infra). 
 
FINRISK/DILGOM Study. The 
participants took part in two phases of the 
National FINRISK 2007 Study conducted 
by the National Institute for Health and 
Welfare in Finland (Vartiainen et al., 
2010). An independent random sample of 
10 000 men and women aged 25 to 74 
years was drawn from the national 
population register in five geographical 
areas at the end of 2006. The sample was 
stratified by sex, 10-year age category and 
area. The first phase took place between 
January and March 2007, and included a 
health examination in local health centres 
or other survey sites by specially trained 
nurses. At this visit, weight, height, waist 
circumference, hip circumference and 
blood pressure were measured and blood 
was drawn. Health questionnaires were 
mailed together with an invitation to the 
health examination. These addressed 
socio-demographic factors, health 
behaviour and medical history and 
included a detailed questionnaire 
regarding weekly (past week) and yearly 
(past year) alcohol consumption. A total of 
6258 participants who took part in the first 
phase of the survey were invited to a more 
detailed examination of the dietary, 
lifestyle and genetic determinants of 
obesity and the metabolic syndrome from 
April to June 2007. This second phase 
comprised the study of the Dietary 
Lifestyle and Genetic Determinants of the 
Development of Obesity and Metabolic 
syndrome (the DILGOM Study) (Saaristo 
et al., 2007). It also included 
anthropometric measurements and 
collection of blood samples to determine 
concentrations of fasting plasma glucose, 
serum insulin and lipids. The response rate 
to the second phase was 80%, and thus the 
cohort included 5024 subjects. The 
protocol was approved by the Ethics 
Committee of Helsinki and Uusimaa 
Hospital District. Written informed 
consent was obtained from all the 
participants for both field research phases.  
 
FIN-D2D Study. The Programme for 
Prevention of Type 2 Diabetes in Finland 
(FIN-D2D) was carried out in three 
hospital districts in Finland between 
October and December 2007 (Männistö et 
al., 2014). A random sample of 4500 
subjects aged 45 to 74 years (stratified 
according to gender, 10-year age groups 
and the three geographical areas) was 
selected from the National Population 
Register. The overall participation rate was 
64%. Nineteen subjects were excluded 
from analyses due to missing 
anthropometric data. The total number of 
individuals included was thus 2849 
representing 63% of the random sample. 
The subjects were invited by mail to a 
clinical examination. They also received a 
self-administered questionnaire on 
medical history and health behaviour, 
which included a detailed questionnaire 
regarding weekly (past week) and yearly 
(past year) alcohol consumption. The 
questionnaire was filled in at home and 
brought to the health examination. A 
trained nurse measured body composition 
and drew blood for measurement of fasting 
plasma glucose, serum insulin, lipids, 
HbA1c and liver enzyme concentrations. All 
samples were collected after an overnight 
fast. The study protocol was approved by 
the Ethics Committee of the Hospital 
District of Helsinki and Uusimaa, and all 
participants gave their written and 
informed consent. 
 
Liver Fat Cohort. 368 non-diabetic 
subjects participated in a metabolic study. 
The subjects were studied after an 
overnight fast. Body composition was 
measured as detailed later in section 4.2.4. 
Blood was drawn for measurement of 
complete blood count, serum total, HDL 
and LDL cholesterol, triglyceride and 
plasma glucose concentration, and HbA1c, 
serum insulin and C-peptide, and ALT,




AST and GGT concentrations. Blood 
samples were also taken for genotyping 
PNPLA3 at rs738409 as described below in 
section 4.2.6. On another occasion, liver fat 
was measured with 1H-MRS. Data on 273 
subjects has been reported before 
(Kotronen, Peltonen, et al., 2009). 
 
Inter-laboratory variation study. Ten 
non-diabetic volunteers covering a wide 
range of insulin sensitivity were recruited 
in May 2016. The subjects were healthy 
based on medical history, physical 
examination and standard laboratory tests 
but 8 of them had BMI ≥25 kg/m2. Blood 
was drawn in Helsinki after a 12-h fast for 
measurement of fasting insulin, glucose, 
HDL, LDL and total cholesterol, 
triglycerides, AST, ALT, GGT, ferritin and 
albumin. Measurements of biochemical 
markers other than insulin and glucose 
were performed for comparative purposes 
to estimate their inter-assay CVs. In 
Helsinki, the samples were analysed 
immediately. Another set of samples were 
instantly frozen to -80 °C and then thawed 
and assayed the same day in Helsinki to 
study the effect of freezing. To study the 
effect of time, a third set of samples were 
instantly frozen to -80 °C, and thawed and 
assayed after 2 weeks in Helsinki. At this 
same time point, six additional sets of 
samples, which had been shipped to the 
participating centres on dry ice, were 
thawed and assayed at Newcastle 
University (Newcastle, UK), Johannes 
Gutenberg University Mainz (Mainz, 
Germany), the Institute of Clinical 
Physiology (Clinical and Research 
laboratories) (Pisa, Italy), the University of 
Torino (Torino, Italy), and the Institute of 
Cardiometabolism and Nutrition (Paris, 
France). The study protocol was approved 
by the Ethics Committee of Helsinki 
University Central Hospital and was 
carried out in accordance with the 
Declaration of Helsinki. Each participant 
provided written informed consent.  
 
 
4.1.4. pIGFBP-1 in NAFLD 
 
378 subjects participated in metabolic 
studies. The subjects were studied after an 
overnight fast. Body composition was 
measured as detailed later in section 4.2.4. 
Blood was drawn for measurement of 
plasma glucose concentration, serum total, 
HDL and LDL cholesterol, triglycerides, 
HbA1c, insulin, C-peptide, pIGFBP-1, ALT, 
and AST concentrations. Blood samples 
were also taken for genotyping PNPLA3 at 
rs738409 as detailed later in section 4.2.6. 
On another occasion, liver fat was 
measured using 1H-MRS. Data on the 
subjects had been reported previously 




4.2.1. Systematic review (II) 
 
A systematic search using PubMed and 
Ovid MedLine was performed in October 
2015 on two topics.  
 
i) To identify definitions of normal liver 
fat, the following search terms and their 
combinations were used: ‘normal liver fat’, 
combined with ‘liver histology’, ‘liver 
biopsy’, ‘liver H-MRS’, ‘liver MRI’, ‘liver 
MRI-PDFF’, ‘liver CT’ and ‘liver 
ultrasound’. Out of the 526 hits, 33 studies 
matched the criteria and assessed normal 
liver fat content or comparison of liver fat 
content using different techniques and 
were hence included in the review.  
 
ii) The association between insulin 
resistance and NAFLD due to PNPLA3 
I148M or TM6SF2 E167K variant was 
assessed by performing a systematic search 
using the following search terms: 
‘PNPLA3’ or ‘TM6SF2’ combined with 
‘insulin resistance’, ‘euglycemic 
[hyperinsulinemic] clamp’, ‘fasting 
glucose’, ‘fasting insulin’, ‘HOMA-IR’ and 
‘oral glucose tolerance test [OGTT]’. From 
the 124 studies matching the search terms, 
22 studies included data on liver fat 
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content between carriers and non-carriers 
of either PNPLA3 I148M or TM6SF2 
E167K variant and on insulin sensitivity 
assessed by the aforementioned methods, 
and were thus included. 
 
4.2.2. Liver fat content using 1H-MRS (I, III, 
IV)  
 
Three generations of 1.5 Tesla clinical 
scanners, Vision, Sonata and Avanto, 
manufactured by Siemens Healthcare 
Diagnostics (Erlangen, Germany) were 
used in the measurements and thus the 
intensity differences arising from various 
acquisition parameters and localization 
techniques had to be normalized. T1-
weighted localisation images were 
collected using a standard 1H body coil. An 
8 to 27 cm3 1H-MRS voxel was carefully 
positioned in the right lobe of the liver 
avoiding subcutaneous fat, large vessels, 
bile ducts and gall bladder. Localization 
was carried out using the STEAM sequence 
with TE (echo time)/TM (mixing time)/TR 
(repetition time) of 20/30/3000 ms and 
32 acquisitions for Vision measurements 
and PRESS sequence with TE/TR of 
30/3000 ms and 16 acquisitions for Sonata 
and Avanto measurements. Subjects were 
breathing normally during the data 
collection. All spectra were analysed with 
the MRUI/jMRUI software using 
VARPRO/AMARES (www.mrui.uab.es/ 
mrui/). The intensities of the peaks 
resonating from the protons of water, and 
protons of methylene [(CH2)n−2] groups in 
the fatty acid chains were determined 
using lineshape fitting with prior 
knowledge. Signal intensities were 
corrected for T1 and T2 relaxation using 
the equation Im=I0 exp(−TE/T2)*[1− 
exp(−(TR−TM−0.5TE)/T1)]*exp(−TM/T1) 
for Vision data and the equation Im=I0 
exp(−TE/T2) for Sonata/Avanto data. T1 
of 600 ms (Stanisz GJ et al., 2005) and 
300 ms (Graham et al., 1999) and 
experimentally determined T2 of 46 ms 
and 58 ms were used for water and fat, 
respectively. Liver fat content was 
expressed as a ratio of signal from 
methylene group to total signal of 
methylene and water. Liver fat content was 
converted from signal ratio to a weight 
fraction, applying method validated by 
Longo et al. (Longo et al., 1995) and 
Szczepaniak et al. (Szczepaniak et al., 
2005). The following experimentally 
determined factors were used: i) the ratio 
of the number of lipid protons in the fitted 
(CH2)n-2 signal to the total number of lipid 
protons is 0.6332 (Szczepaniak et al., 
1999); ii) proton densities of fat and water 
are 111 and 111 mol/l, respectively; iii) 1 g 
liver tissue contains 711 mg water; iv) 
densities of the liver tissue, fat in the liver, 
and water are 1.051 g/ml, 0.900 g/ml, and 
1.000 g/ml; respectively. All spectra were 
analysed by a physicist who was unaware 
of the clinical data. NAFLD was defined as 
liver fat ≥55.6 mg triglyceride/g liver tissue 
or >5.56% of liver tissue weight as in the 
DHS  (Szczepaniak et al., 2005).  
 
4.2.3. Adipocyte size and number (I) 
 
SC adipocyte size was determined using 
the collagenase digestion method (Rodbell, 
1964). In brief, adipose tissue from a 
needle aspiration biopsy was transferred 
into a 2 ml plastic vial that contained 
collagenase buffer (100 mg of collagenase 
[C-6885, Type II, Sigma-Aldrich, St. Louis, 
MO], 0.1 ml of a 550 nM glucose solution 
and 35 ml 10% albumin in HEPES buffer 
in a total volume of 100 ml). The sample 
was incubated in a water bath at 37 ̊C for 
one hour. The adipocytes that floated on 
the surface were then transferred into 
counting vials using a disposable syringe 
(Bürker, Marienfeld-Superior, Lauda-
Könighofen, Germany). Adipocyte cell 
sizes were analysed using a light 
microscope (Leica DM750 Led, Wetzlar, 
Germany) equipped with a caliper scale, 
and the ‘adipocyte size’ was defined as the 
mean size of 100 cells. The total number of 
adipocytes in the body was calculated as 
follows: i) total body fat mass was derived 
from body fat percentage and total body 
weight; ii) total fat volume was calculated 
as fat mass (kg) divided by its density, 
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0.9196 kg/m³ (Abate et al., 1996); iii) 
adipocytes were assumed to be spherical, 
and their volume calculated with the 
formula for the volume of sphere (V=4/3 π 
r³); and iv) the total number of adipocytes 
was derived by dividing total volume of 
whole body fat by the volume of a single 
adipocyte. 
 
4.2.4. Body composition (I, III, IV)  
 
During the metabolic study visit, body 
weight was recorded to the nearest 0.1 kg 
using a calibrated digital scale (Soehnle, 
Monilaite-Dayton, Finland) with the 
subject barefoot and wearing light indoor 
clothing. Height was recorded to the 
nearest 0.5 cm using a non-stretchable 
tape. BMI was defined as [weight 
(kg)]/[height (m2)]. Waist circumference 
was measured midway between superior 
iliac spine and the lower rib margin, and 
hip circumference at the level of the 
greater trochanters. Fat free mass and 
body fat percentage were determined using 
bioelectric impedance analysis 
(BioElectrical Impedance Analyzer, model 
#BIA-101A;RJL Systems, Detroit, MI).  
 
4.2.5. IA and SC adipose tissue volume (I) 
 
The MRI studies were carried out using the 
same scanners as detailed 4.2.2. A series of 
T1-weighted transaxial images were 
acquired from a region extending from 8 
cm above to 8 cm below the L4/5 
intervertebral disc (16 slices, field of view 
375 x 500 mm2, slice thickness 10 mm, 
breath-hold repetition time 138.9 ms, echo 
time 4.1 ms), as previously described 
(Ryysy et al., 2000). For the data collected 
with Siemens Vision, the IA and SC fat 
areas were calculated in a blinded fashion 
using an image analysis program (Alice 
3.0, Parexel, Waltham, MA). The data 
collected with Siemens Sonata and Avanto 
were analysed using SliceOmatic version 
4.3 (TomoVision, Magog, Canada) 
segmentation software. The areas of the SC 
and IA adipose tissue were measured for 
each slice using a region-growing routine. 
A histogram of pixel intensity in the IA 
region was displayed, and the intensity 
corresponding to the nadir between the 
lean and fat peaks was used as a cut-off 
point. The IA adipose tissue was defined as 
the area of pixels in the intra-abdominal 
region above this cut-off point. For 
calculation of the SC adipose tissue area, a 
region of interest was first manually drawn 
at the demarcation of the SC adipose tissue 
and IA adipose tissue. 
 
4.2.6. Genotyping of PNPLA3 genotype at 
rs738409 (I, III, IV) 
 
Studies I, the Liver Fat Cohort in III and 
IV. Approximately 10 ng of genomic DNA 
extracted from whole blood was used for 
genotyping by the TaqMan PCR method 
(Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s 
instructions. Post-PCR allelic 
discrimination was carried out measuring 
allele-specific fluorescence on an ABI 
Prism Sequence Detection System ABI 
7900HT (Applied Biosystems). As this 
assay is designed for the reverse strand, 
the G allele corresponds to the 148Met 
phenotype while the gene is transcribed 
from the forward strand. The success rate 
for genotyping was >95%. The genotype 
was in the Hardy-Weinberg equilibrium.  
 
FINRISK/DILGOM cohort (III). The 
PNPLA3 genotype was determined from 
1000G imputed GWAS data consisting of 
three subsets genotyped using Illumina 
Human Core Exome, Illumina Omni 
Express and Illumina 610K (Illumina, San 
Diego, CA).  
 
FIN-D2D cohort (III). Genomic DNA was 
extracted from whole blood using 
automated Chemagen DNA extraction 
equipment (PerkinElmer, Waltham, MA), 
or a QIAamp DNA Blood Maxi Kit 
(QIAGEN GmbH, Hilden, Germany) 
following the protocol of the kit with slight 
modifications. Genotyping was performed 
using a TaqMan assay (Applied 
Biosystems, Paisley, UK).  
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4.2.7. S-pIGFBP-1 (IV) 
 
Serum pIGFBP-1 concentrations were 
determined with an immunoenzymatic 
assay (IEMA) with monoclonal antibodies 
(Medix Biochemica, Kauniainen, Finland) 
according to the manufacturer’s 
instructions (Nuutila M et al., 1999). This 
assay uses a monoclonal antibody specific 
to human pIGFBP-1, which is immobilised 
on microwell plates, and a monoclonal 
antibody specific to IGFBP-1, which is 
bound to the microwells and conjugated 
with horse-radish peroxidase. The 
enzymatic reaction is proportional to the 
amount of pIGFBP-1 in the sample. The 
intra-assay CV was 2.7% to 7.8% and inter-
assay CV 3.9% to 10%. Each sample was 
assayed in duplicate and the mean value 
was used. The detection limit of the assay 
was 0.3 µg/l and the measuring range 1 to 
200 µg/l. No cross-reactivity with other 
IGFBPs was detected. All sera were 
analysed after storage at -80°C until 
analysis. 
 
fS-IGFBP-1 was measured by RIA 
(Kotronen, Lewitt, et al., 2008) in 23 
samples that had been stored for 5 years. 
These samples were re-assayed with the 
IEMA for pIGFBP-1. The mean 
concentrations were 18±2 µg/l with the 
RIA and 57±8 µg/l with the IEMA 
(p<0.001 for the difference). The 
concentrations correlated positively 
(r=0.64, p<0.001).  
 
4.2.8. Biochemical analysis (I, III, IV) 
 
I, the Liver Fat Cohort in III and IV: 
Plasma glucose was measured using the 
hexokinase method, serum ALT, AST and 
GGT activities were according to the 
recommendations by the European 
Committee for Clinical Laboratory 
Standards, and serum triglyceride, total, 
LDL and HDL cholesterol concentrations 
in an automatic analyser (Roche 
Diagnostics Hitachi 917, Hitachi Ltd., 
Tokyo, Japan). Serum insulin and C-
peptide concentrations were measured 
using time-resolved fluoroimmunoassay 
with Auto-DELFIA kits (Wallac, Turku, 
Finland). HbA1c was measured using high-
pressure liquid chromatography using a 
fully automated system (Bio-Rad, 
Richmond, CA, US).  
 
FINRISK/DILGOM and FIN-D2D: 
Biochemical assays were performed in the 
Laboratory of Analytical Biochemistry of 
the Institute of Health and Welfare 
(Helsinki, Finland) using Architect ci8200 
analyser (Abbott Laboratories, Abbott 
Park, IL, US). Plasma glucose was 
determined using the hexokinase method 
and serum insulin using a 
chemiluminescent microparticle 
immunoassay. Serum total and HDL 
cholesterol, and triglyceride concentrations 
were measured with enzymatic methods. 
The concentration of LDL cholesterol was 
calculated using the Friedewald formula 
(Friedewald et al., 1972). Total cholesterol 
was measured with the CHOD-PAP-assay. 
Samples were stored at -80 °C before 
analysis. In the FIN-D2D study, HbA1c was 
measured by an immunoturbidimetric 
method and serum ALT, AST, and GGT 
concentrations by using photometric IFCC 
methods.  
 
Inter-laboratory study: Methods used in 
the inter-laboratory study are presented in 
Table 1. 
 
HOMA-IR was calculated as: [fP-glucose 
(mmol/l) x fS-insulin (mU/l)]/22.5. 
 
4.2.9. Statistical analysis (I, III and IV) 
 
The distribution of continuous variables 
was tested for normality using the 
Kolmogorov-Smirnov test. Non-normally 
distributed data were subjected to 
logarithmic transformation. To compare 
characteristics between groups, the 
unpaired t-test and the Mann–Whitney’s U 
test were used for continuous variables, 
and Fisher’s exact test and χ2 test for 
categorical variables when appropriate. 
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Pearson’s correlation coefficient or 
Spearman’s rank correlation coefficient 
were used for univariate analysis (I, III, 
IV). Multiple linear regression analyses 
were performed to identify independent 
determinants of liver fat (I, III, IV). 
Bootstrap randomisation was used to 
randomise the subjects into discovery (2/3 
of subjects) and validation (1/3 of 
subjects) cohorts, and all subjects were 
used as a second validation cohort (III, 
IV). P-values <0.05 were considered 
statistically significant. Normally 
distributed data are shown as mean ± SD, 
whereas non-normally distributed are 
shown as median (25–75th percentile). 
The calculations were performed using 
GraphPad Prism (versions 4.03 and 6.00, 
GraphPad Software Inc., San Diego, CA), 
SPSS Statistics (versions 17.0 and 21.0, 
SPSS Inc., Chicago, IL), Microsoft Office 
Excel (versions 2007 and 2011, Microsoft, 
Redmond, WA) and the R Project (version 
3.1.1, www.r-project.org, Vienna, Austria). 
 
Adipocyte size in NAFLD (I) 
 
Spearman correlation coefficient was used 
to determine correlates of liver fat 
content. Partial correlation analysis was 
used to control for known covariates of 
liver fat. One-way ANOVA was used to 
compare liver fat content between the 
PNPLA3 genotypes. Multiple linear 
regression analysis was used to search for 
independent predictors of liver fat 
content. Predictive models were compared 
using the F-test based on the residual sum 
of squares adjusted for the total number of 
variables in each model. 
 
Reference value for HOMA-IR (III) 
 
HOMA-IR was not normally distributed 
and therefore the 95th percentile (90% CI) 
rather than the mean + 2 SD was used to 
determine the upper reference value for 
HOMA-IR (Horn and Pesce, 2003). To 
evaluate the effect of BMI and gender, 
values of HOMA-IRs were subjected to 
log2 transformation and further adjusted 
in a generalised linear model by using age 
and BMI as covariates. The 95th percentile 
was also defined for S-ALT in the FIN-
D2D cohort. 
 
Determination of an optimal HOMA-IR cut-
off value for NAFLD (III) 
 
The HOMA-IR value corresponding to the 
normal liver fat based on the DHS (liver 
fat=5.56%) was calculated using linear 
regression analysis. We tested whether the 
slopes and intercepts in linear regression 
analysis differed between men and 
women, and carriers and non-carriers of 
the PNPLA3 I148M variant. The 95th 
percentile of liver fat in the healthy 
subjects of the Liver Fat Cohort was used 
to define normal liver fat content as in the 
DHS (Szczepaniak et al., 2005).  
 
The discovery group was used to 
determine the ROC curve for HOMA-IR 
and AUROC (95% CI). The Youden Index, 
which indicates the point of optimal 
sensitivity and specificity (Greiner et al., 
2000), was calculated to define the 
optimal cut-off of HOMA-IR to identify 
subjects with or without NAFLD. The 
validation group and all subjects were 
used for validation. For additional 
validation, we generated 1000 random 
sets of samples and used the bootstrap 
method to validate the model in the 
sample sets. The AUROC of each set was 
estimated, and the average of these 
estimates provided the overall prediction 
accuracy of the model. Power analysis was 
conducted to estimate the appropriate 
sample size for correlation analysis and 
ROC analysis. To detect a correlation 
coefficient of 0.2 between HOMA-IR and 
liver fat content with a power of 0.8, a 
sample size of at least 193 was required. 
By setting the ratio of sample sizes 
between negative and positive groups at 2, 
at least 23 cases and 46 control 
participants were needed to reach a 
statistical power of 0.8 to detect the 
minimum AUROC of 0.7.  
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The inter-laboratory variation of HOMA-IR 
and other analytes (III) 
 
The inter-laboratory CVs of fasting 
insulin, glucose and HOMA-IR, lipids, 
liver enzymes, ferritin and albumin 
between laboratories were calculated as a 
the ratio of SD to mean. Linear regression 
analyses were performed to compare 
insulin, glucose and HOMA-IR 
measurements in Helsinki to those in 
other centres. Equations from these linear 
regression curves were used to define the 
HOMA-IR in each centre corresponding to 
the upper reference limit for HOMA-IR in 
Helsinki.  
 
fS-pIGFBP-1 in NAFLD (IV) 
 
Linear regression and Random Forest 
prediction models were used to estimate 
the liver fat content. For both models, 
variables that significantly correlated with 
liver fat in univariate analyses in the 
discovery group were used. One variable 
from each group of variables reflecting the 
same biological phenomenon (body 
composition, liver enzymes, glycaemia, 
insulinemia and lipids) was entered into 
the models to avoid multi-collinearity. 
Using a sample size of 378 subjects, a 
power of 0.8 and a P-value of 0.05, a 
linear correlation coefficient of 0.144 or 
over can be detected. 
 
Multiple linear regression analysis was 
used to create an equation to estimate 
liver fat content. The final variables for 
this were derived from a backward 
stepwise regression method based on 
Akaike Information Criteria (AIC). The 
model was evaluated using adjusted 
coefficient of determination (R2). 
Predictive models were compared using 
the F-test based on the residual sum of 
squares adjusted for the total number of 
variables in each model.  
 
To compare the accuracy of the equation 
created using multiple linear regression 
with FLI (Bedogni et al., 2006) and HSI 
(Lee et al., 2010), their respective 
reference values were used and for the 
created equation the 5.56% reference 
value as a cut-off for NAFLD (Szczepaniak 
et al., 2005). The ROC curve was 
determined to calculate AUROC for each 
predictive model, and the AUROCs were 
compared using the DeLong method 
(DeLong et al., 1988).  
 
In the Random Forest modelling, the 
optimal number of variables on each tree 
was defined based on the estimation of 
out-of-Bag error. By using the predictors 
described above, 500 regression trees 
were trained in the discovery group. The 
predictability of each variable was 
estimated by cross-validating its 
relationship with the outcome in the 
validation group and all subjects. A 
variable importance plot based on the 
importance score summarised the 
importance of each predictor. Correlation 
coefficients were compared statistically 








5.1. SUBJECT CHARACTERISTICS (I, 
III–IV) 
 
Physical and biochemical parameters of 
the study subjects in studies I, III and IV 
are shown in Table 2. 60% to 70% of study 
subjects were women and the median age 
was between 42 and 55 years. Apart from 
the FINRISK/DILGOM and FIN-D2D 
cohorts, which were by definition non-
obese, the study subjects were mostly 
overweight or obese. 35% to 46% of the 
subjects had NAFLD (studies I, the Liver 
Fat Cohort in III and IV). 51% to 60% did 
not carry the PNPLA3 I148M gene variant.  
 
5.2. ADIPOCYTE SIZE IN NAFLD (I) 
 
In this study, women had significantly 
higher HDL cholesterol concentration, 
abdominal SC adipose tissue volume and 
adipocyte number than men (p<0.0005), 
whereas men had a significantly higher 
waist-to-hip ratio and fS-ALT 
concentration (p<0.005) (I, Table 1).  
 
5.2.1. Adipocyte size and liver fat 
	
The median (25–75%) adipocyte size was 
112 (96.2–120) µm and adipocyte number 
4.07 (3.29–5.28) x 109. Adipocyte size 
correlated significantly with liver fat (all 
subjects ρ=0.50, p<0.0001; for men 
ρ=0.67, p<0.0001; and for women 
ρ=0.41, p<0.0001). Other parameters that 
correlated with liver fat in univariate 
analysis included age (ρ=0.30, p=0.001), 
measures of obesity, fS-insulin (ρ=0.59, 
p<0.0001), fS-C-peptide (ρ=0.54, 
p<0.0001), measures of glycaemia, fP-
triglycerides (ρ=0.44, p<0.0001), liver 
enzymes, and PNPLA3 genotype (I, Table 
1). Adipocyte number did not correlate 
significantly with liver fat content 
(p=0.18). 
 
The relationship between adipocyte size 
and liver fat remained significant after 
adjustment for the factors known to 
regulate liver fat content, i.e., age, gender, 
BMI, PNPLA3 genotype and the IA/SC 
adipose tissue volume ratio (adjusted 
correlation coefficient for all subjects 
ρ=0.44, p<0.0001), Fig. 1. 
 
To determine whether adipocyte size is an 
independent determinant of variation in 
liver fat, results of the univariate analysis 
and physiologically plausible regulators of 
liver fat (adipocyte size, body fat 
distribution, BMI, PNPLA3 genotype, age, 
gender) were subjected to multiple linear 
regression analysis. A model including 
age, BMI, IA/SC adipose tissue ratio, 
PNPLA3 genotype and adipocyte size 
accounted for 53% of the variation in liver 
fat (Table 3), and exclusion of adipocyte 
size reduced the explanatory power of the 
model significantly to 42% (p<0.0001). 
Gender did not remain significant 
(p=0.07). 
 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1.  
 
Figure 1. Correlation between liver fat content and adipocyte diameter controlled with age, gender, BMI, PNPLA3 
genotype, IA/SC adipose tissue volume ratio (ρ=0.44, p<0.0001). Full circles, men; open circles, women. 












Age (log10) -0.74 0.32 0.022 
BMI 0.033 0.008 <0.0001 
IA/SC adipose tissue volume (log10) 0.78 0.18 <0.0001 
PNPLA3 genotype* 0.29 0.057 <0.0001 
Adipocyte size (log10) 3.35 0.67 <0.0001 
* 1=I148II, 2=I148IM, 3=I148MM. BMI, body mass index; IA, intra-abdominal; PNPLA3, patatin-like phospholipase 
domain containing 3; SC, subcutaneous. Adapted from Petäjä EM et al. Obesity 2013; 21: 1174-9 and reproduced 
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Table 4. Definitions of normal liver fat using liver histology, 1H-MRS, MRI, CT and US 
 Subjects Definition of normal liver fat 
Histology   
Kleiner DE et al. 2005 576 adults and 162 children Macroscopic fat in <5% of hepatocytes  
Brunt EM et al. 2011 976 adults Macroscopic fat in <5% of hepatocytes  
Bedossa P et al. 2012 679 morbidly obese subjects Macroscopic fat in <5% of hepatocytes 
1H-MRS   
Szczepaniak LS et al. 2005 345 healthy subjects, 
population-based study 
<5.56%  
Petersen KF et al. 2006 170 healthy subjects <3.0% 
MRI   
Fishbein MH et al. 1997 28 healthy subjects <9.0% 
CT   
Piekarski J et al. 1980 100 healthy subjects 50-57 HU or 8-10 HU higher than spleen 
US   
Joseph AE et al. 1978 60 adults referred to 
gastroenterologists 
Absence of echogenicity or brightness 
of the liver 
Saverymuttu SH et al. 1986 490 adults referred to 
gastroenterologists 
Absence of echogenicity or brightness 
of the liver  
1H-MRS, proton magnetic resonance spectroscopy; CT, computed tomography; MRI, magnetic resonance 
spectroscopy; US, ultrasound. Adapted from Petäjä EM & Yki-Järvinen H. Int J Mol Sci 2016; 17: 633 and reproduced 
with the permission of MDPI (Creative Commons Attribution Licence). 
 
 
5.3. DEFINITIONS OF NORMAL 
LIVER FAT (II) 
 
The definitions of normal liver fat that 
were found in the systematic review are 
shown in Table 4. The biochemical 
definition of normal liver fat determined 
in 107 cadavers was 5.5 g of triglycerides 
in 100 g of wet liver tissue (Donhoffer, 
1974) 
 
5.3.1. Histology of liver biopsy 
 
Histologically, normal liver fat is defined 
as less than 5% of hepatocytes containing 
macrovesicular steatosis (Kleiner et al. 
2005; Bedossa et al., 2012; Brunt and 
Tiniakos, 2010) (Table 4). Steatosis was 
graded by the pathologist from 0 to 3 
based on its severity: grade 0 (normal): 
<5%; grade 1 (mild): 5% to 33%; grade 2 
(moderate): 34% to 66%; and grade 3 
(severe): ≥67% of hepatocytes 
characterised by macroscopic steatosis 
(Kleiner et al. 2005). Kleiner et al. 
developed the NAS score in 576 adults and 
162 children of whom liver biopsy was 
obtained (Kleiner et al. 2005), and 58 of 
the adults and 5 of the children had <5% 
macroscopic liver fat. Bedossa et al. 
developed the SAF score in 679 morbidly 
obese subjects undergoing bariatric 
surgery, and of them 158 subjects had 
<5% of macroscopic liver fat (Bedossa et 
al., 2012). No population-based studies 
exist, as obtaining a liver biopsy without a 




Using 1H-MRS, normal liver fat content 
has only been studied in one population-
based study, the DHS. Normal liver fat 
was defined as the upper 95th percentile of 
liver fat content in healthy subjects. 1H-
MRS was performed on 2349 subjects, of 
whom 345 were considered healthy based 
on the following criteria: no history of 




 steatosis (alcohol consumption ≤30 g/day 
in men, ≤20 g/day in women, BMI <25 
kg/m2, normal fasting serum glucose, 
non-diabetic and normal serum ALT [≤30 
U/l in men, ≤19 U/l in women]). The 
upper 95th percentile of liver fat content in 
healthy subjects was 5.56% (Szczepaniak 
et al., 2005) (Table 4). This criterion is 
recognised as the standard criteria for the 
diagnosis of NAFLD using 1H-MRS. 
Another study comprised 170 Caucasian 
subjects described as young, lean and 
healthy, but the criteria were not 
presented (Petersen et al., 2006). The 
upper 95th percentile of liver fat content 
using 1H-MRS was 3.0% (Table 4).  
 
1H-MRS-determined liver fat corresponds 
well to triglyceride content measured in a 
liver biopsy (r=0.90, p<0.001) (Thomsen 
et al., 1994). The relationship between 
liver fat content evaluated by 1H-MRS and 
percentage of macroscopic liver fat was 
analysed in three studies, which included 
13 (Kotronen, Vehkavaara, et al., 2007), 
12 (Cowin et al., 2008) and 50 
(Noureddin et al. 2013) subjects. In the 
first two studies, the 1H-MRS-determined 
normal liver fat in the DHS, i.e., 5.56%, 
corresponded to 15.7% (Kotronen, 
Vehkavaara, et al., 2007) and 13.9% 
(Cowin et al., 2008) of macroscopic 
steatosis. In the third study, histological 
grade 1 corresponded to 11% (7%–14%), 
grade 2 to 18% (14%–23%), and grade 3 to 
25% (10%–28%) liver fat as measured by 
1H-MRS (Noureddin et al. 2013). Thus, 
normal liver fat content determined in 
liver histology, i.e. the percentage of 
hepatocytes with macroscopic steatosis, is 
approximately 2 to 3 times higher than the 




No population-based studies defining 
normal liver fat using the modified Dixon 
method or the MRI-PDFF method exist. 
The only study that has quantified liver fat 
in healthy subjects used the modified 
Dixon method, and defined normal liver 
fat as <9.0% in 28 healthy subjects 
(Fishbein et al., 1997) (Table 4). No study 
assessing normal liver fat content in 
healthy subjects has been performed using 
MRI-PDFF, however the value of 5.6% 
derived in the DHS for 1H-MRS (Reeder 
and Sirlin, 2010; Rehm et al., 2015) or a 
value of 5.0% (Noureddin, et al. 2013; 
Yokoo et al., 2009) are widely used.  
 
Liver fat content measured using the MRI-
PDFF method correlates closely with that 
determined from liver histology (8.9%–
9.4% at grade 1, 15.8%–16.3% at grade 2, 
and 22.1%–25.0% at grade 3, p<0.0001) 
(Noureddin et al. 2013; Patel et al., 2013; 
Permutt et al., 2012; Tang et al., 2013) 
and measured using 1H-MRS (r=0.99) 
(Idilman et al., 2015; Kang et al., 2012; 
2011; Noureddin et al. 2013). The 5% 
macroscopic liver fat corresponded to a 
PDFF value of 6% in 70 subjects (Idilman 
et al. 2013) and 6.4% in 12 adults and 65 
children (Tang et al., 2013). The best cut-
off for MRI-PDFF-derived liver fat% to 
distinguish steatosis grade 0 (<5% 
steatosis) from grade 1–3 was defined in 
three studies: in 152 subjects as 5.2% of 
liver fat (Imajo et al., 2016), in 97 subjects 
as 4.5% of liver fat (Kühn et al., 2012) and 
in 56 subjects as 2.9% of liver fat (Kang et 
al., 2012).  
 
5.3.4. CT  
 
In subjects with hepatic steatosis, the 
mean attenuation of the liver is lower than 
that of the spleen, and the liver appears 
darker than the spleen. In a study of 100 
healthy adults, the attenuation in the 
healthy liver was 50 to 57 Houndsfield 
Units (HU) and 8 to 10 HU higher than 
the attenuation of spleen (Piekarski et al., 
1980) (Table 4). The attenuation value 
decreases by 1.6 HU for 1 mg of 
triglycerides per 1 g of liver tissue (Bydder 
et al., 1981). Attenuation values <40 HU 
in the liver or 10 HU less in the liver than 
in the spleen are indicative of marked 
hepatic steatosis (>30%) (Hamer et al., 
2005). 





In studies consisting of 60 (Joseph et al., 
1978) and 490 adults (Saverymuttu et al., 
1986) referred to gastroenterologist, 
normal liver fat was defined as absence of 
echogenicity or brightness of the liver 
(Table 4). Steatosis is scored semi-
quantitatively as ‘mild’, ‘moderate’, or 
‘severe’ based upon the visual assessment 
of hepatic echogenicity (Joseph et al., 
1978; Needleman et al., 1986; 
Saverymuttu et al., 1986). Mild steatosis is 
seen as a slight increase in liver 
echogenicity. In moderate steatosis, 
visualisation of intrahepatic vessels and 
the diaphragm is slightly impaired, and 
increased liver echogenicity was present. 
Severe steatosis is characterised as a 
marked increase in hepatic echogenicity, 
poor penetration of the posterior segment 
of the right lobe of the liver, and poor or 
no visualization of the hepatic vessels and 
diaphragm (Jain KA et al., 1993). A meta-
analysis of 44 studies comprising 4720 
subjects concluded that US has a 
sensitivity of 85% and a specificity of 94% 
for detecting 20%–30% macroscopic 
steatosis (Hernaez et al., 2011). The 
sensitivity and specificity were 65% and 
81% for detecting 0%–5% steatosis and 
93% and 88%, respectively, for detecting 
>10% steatosis.  
 
5.4. INSULIN SENSITIVITY IN 
GENETIC NAFLD (II) 
 
5.4.1. ‘PNPLA3 NAFLD’ 
	
Table 5 summarises the 14 studies that 
include data on insulin sensitivity in 
carriers and non-carriers of the I148M 
variant (Del Ben et al., 2014; Kantartzis et 
al., 2009; Kotronen, Johansson, et al., 
2009; Lin et al., 2011; Musso et al., 2015; 
Park, Cho, Kwon, Prilutsky, Yun, Choi, 
Hwang, Lee, Kim, and Kong, 2015b; 
2015a; Romeo et al., 2008; Romeo, 
Sentinelli, Cambuli, et al., 2010; Scorletti 
et al., 2015; Valenti, Al-Serri, et al., 2010; 
Valenti, Alisi, et al., 2010; Verrijken et al., 
2013; Wagenknecht et al., 2011; Wang et 
al., 2011). These studies comprised 8425 
subjects, and included obese and non-
obese as well as diabetic and non-diabetic 
subjects. Three studies were performed in 
paediatric cohorts. In 12 studies, the 
carriers of the PNPLA3 I148M variant had 
significantly more liver fat or significantly 
higher prevalence of steatosis than non-
carriers. HOMA-IR was used in 12 of the 
14 studies as a marker of insulin 
sensitivity. Two studies used other 
methods: one OGTT (Kantartzis et al., 
2009) and the other fS-insulin 
concentration and the hyperinsulinemic 
clamp (Kotronen, Johansson, et al., 
2009). In 12 studies, no significant 
difference was found in HOMA-IR or 
other insulin sensitivity markers between 
carriers and non-carries. One study did 
not report the data but stated that the 
gene variant did not correlate with 
HOMA-IR or the insulin sensitivity index 
(Wagenknecht et al., 2011). In one study, 
the homozygous carriers had significantly 
lower HOMA-IR than the non-carriers or 
the heterozygous carriers despite higher 
prevalence of steatosis (Park JH et al., 
2015). Serum triglycerides were reported 
in 12 studies. In 9 of these, there was no 
difference in serum triglyceride 
concentrations. Two studies found the 
carriers of the variant to have lower 
triglyceride concentrations and one study 
found the carriers to have higher 
triglyceride concentrations than the non-
carriers. 
 
5.4.2. ‘TM6SF2 NAFLD’ 
 
Table 6 summarizes seven studies that 
have reported data on liver fat content and 
insulin sensitivity in carriers and non-
carriers of the TM6SF2 E167K allele 
(Eslam et al., 2016; Goffredo et al., 2016; 
Grandone et al., 2016; Kozlitina et al., 
2014; Scorletti et al., 2015; Sookoian et 
al., 2015; Zhou et al., 2015). The studies 
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paediatric cohorts. In six of these studies, 
the carriers had a significantly higher liver 
fat content, determined by 1H-MRS or 
MRI, or higher prevalence of steatosis, 
determined by histology or US, than non-
carriers. One study found no difference in 
liver fat content between the two groups 
(Scorletti et al., 2015). There was no 
difference in insulin sensitivity, 
determined by HOMA-IR or OGTT, 
between the carriers and non-carriers. 
Serum triglyceride concentrations were 
lower in three studies (Eslam et al., 2016; 
Grandone et al., 2016; Scorletti et al., 
2015), similar in three studies (Goffredo et 
al., 2016; Kozlitina et al., 2014; Zhou et 
al., 2015) and higher in one study 
(Sookoian et al., 2015) in the TM6SF2 
E167K allele carriers compared to non-
carriers.  
 
5.5. REFERENCE VALUES FOR 
HOMA-IR (III) 
 
Characteristics of the healthy subjects in 
the two population-based cohorts (n=1167 
for the FINRISK/DILGOM and n=459 for 
the FIN-D2D cohort) are shown in Table 
2.  
 
5.5.1. Reference value for HOMA-IR in two 
population-based cohorts 
 
The upper reference limit (95th percentile 
[90% CI)]) of HOMA-IR was 1.9 (1.8 –2.0) 
in the FINRISK-/DILGOM cohort and 2.0 
(1.9–2.2) in the FIN-D2D cohort. There 
was no significant difference between the 
HOMA-IRs in either cohort between 
genders (Table 7). In both cohorts, men 
were slightly more obese and older (III, 
Table 1) and to correct for this, age- and 
BMI-adjusted HOMA-IRs were calculated. 
The adjusted HOMA-IRs were very 
similar compared to the unadjusted values 
(in the FINRISK/DILGOM 1.0 [0.9–1.1] in 
all subjects, 1.0 [0.9–1.1] in women and 
1.08 [1.0–1.1] in men, p=0.0007 between 
genders, and in the FIN-D2D 1.1 [1.0–1.2] 
in all subjects, 1.1 [1.0–1.2] in women and 
1.1 [1.1–1.2] in men, p=0.0019). No 
significant difference was observed in the 
clinical characteristics between the 
carriers and non-carriers of the PNPLA3 
I148M variant (III, Supp. Table 1). The 
95th percentiles of HOMA-IR between the 
PNPLA3 I148M non-carriers and carriers 
were similar (Table 7). 
 
5.6. OPTIMAL HOMA-IR CUT-OFF 
FOR NAFLD (III) 
 
Characteristics of the non-diabetic 
subjects (n=368) are shown in Table 2. 
  
5.6.1. HOMA-IR corresponding to normal 
liver fat 
 
HOMA-IR and liver fat content correlated 
significantly (r=0.67, p<0.0001 in all 
subjects; r=0.67, p<0.0001 in men 
r=0.66, p<0.0001 in women). In linear 
regression analysis, the HOMA-IR 
corresponding to NAFLD as defined as in 
the DHS (liver fat=5.56%) was 2.0 (1.9–
2.1) (III, Fig. 2a) in all subjects, 1.9 (1.8–
2.1) in women and 2.1 (1.9–2.2) in men 
(slopes p=0.79, elevations p=0.75). 
 
The HOMA-IR corresponding to normal 
liver fat content was significantly higher 
(2.1 [2.0–2.2] vs. 1.8 [1.6–1.9], slopes 
p=0.99, intercepts p=0.007) in non-
carriers than carriers of the PNPLA3 
I148M variant (III, Fig. 2b) (correlation 
r=0.68, p<0.0001 in non-carriers; r=0.66, 
p<0.0001 in carriers of the variant). This 
causes the variant allele carriers to be 
significantly more insulin sensitive than 
the non-carriers for a given liver fat 
content.  
 
The upper 95th percentile for liver fat in 
the 96 healthy (defined as in the DHS) 
(n=96) subjects was 5.9%. 
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5.6.2. Optimal HOMA-IR cut-off to 
diagnose NAFLD 
 
ROC analysis was performed to define the 
optimal cut-off for HOMA-IR to 
distinguish NAFLD from non-NAFLD. 
Subjects were randomised into discovery 
(2/3) and validation (1/3 of subjects) 
groups that matched with respect to 
clinical characteristics. The AUROC for 
HOMA-IR was 0.88 (95% CI 0.84–0.92) 
in the discovery group (Fig. 2). The 
optimal cut-off for NAFLD based on the 
Youden Index was a HOMA-IR of 1.9. This 
cut-off had a sensitivity of 87%, specificity 
of 79%, negative predictive value (NPV) of 
92% and positive predictive value (PPV) 
of67%. The results were similar for the 
validation group (Fig. 2): AUROC 0.80 
(0.70–0.88), sensitivity 68%, specificity 
82%, NPV 81%, and PPV 70%, and for all 
subjects: AUROC 0.85 (0.80–0.89), 
sensitivity 80%, specificity 80%, NPV 
88%, and PPV 68%. The AUROC for 
bootstrap samples was 0.88 (0.82–0.92) 
and the overall estimate of optimism was 
0.00079. Neither gender (p=0.50) nor 
PNPLA3 genotype (p=0.21) significantly 
improved the AUROC.  
 
5.6.3. Inter-laboratory variation in insulin 
assays and HOMA-IR 
 
Table 2 shows the clinical characteristics 
of 10 subjects. The mean insulin 
concentrations from seven laboratories 
ranged from 3.0 to 15.2 mU/l, glucose 
from 4.7 to 6.1 mmol/l and HOMA-IR 
from 0.69 to 4.0 (Table 8). Freezing and 
thawing the serum the same day had no 
impact on fasting insulin (8.8±4.8 mU/l 
vs. 9.0±4.9 mU/l, p=0.077). Serum insulin 
concentrations decreased over time when 
stored at -80°C degrees for two weeks 









Figure 2. AUROC for HOMA-IR and NAFLD. The 
AUROC for HOMA-IR was 0.88 (95% CI 0.84-0.92) 
in the discovery group (solid line), 0.80 (0.70-
0.88) in the validation group (dashed line) and 
0.85 (0.80-0.89) in all individuals (dotted line). 
Reproduced from Isokuortti E et al., Diabetologia 
2017:60;1873-1882 and with the permission of 
Springer Berlin Heidelberg. 
 
 
Table 8 presents results from 
simultaneous analysis of samples stored at 
-80°C for two weeks in seven participating 
laboratories. The CV of fasting insulin and 
glucose measured in the seven 
laboratories averaged 25.4% and 4.6%, 
respectively. The CV of HOMA-IR was 
25.0% (Table 8). All the CVs with the 
exception of ferritin were significantly 
(p<0.01) lower than the CV for fasting 
insulin.  
 
Correlation coefficients between HOMA-
IR measured in Helsinki and in other 
laboratories are shown in Table 9. The 
slopes differed between Helsinki and 
Newcastle, Mainz and Pisa clinical lab, 
and the intercepts with Torino. The 
HOMA-IR value of 2.0 measured in 
Helsinki corresponded to HOMA-IRs of 
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Table 7. The upper 95th percentile (90% CI) of HOMA-IR in healthy subjects of the 





All subjects  1.9 (1.8-2.0) 2.0 (1.9-2.2) 
      Women  1.8 (1.8-2.0) 2.0 (2.0-2.4) 
      Men 1.9 (1.8-2.0) 2.0 (1.9-2.3) 
      PNPLA3I148II 1.9 (1.8-2.0) 2.0 (2.0-2.2) 
      PNPLA3I148IM/MM 1.8 (1.7-2.0) 2.0 (1.9-2.5) 
CI, confidence interval; PNPLA3, patatin-like phospholipase domain containing 3 gene 
 
 
Table 8. Inter-laboratory variation in 7 European laboratories 
 
 Range Mean SD CV (%) 
fS-Insulin (mU/l) 3.0-15.2 6.79 1.59 25.4 
fP-Glucose (mmol/l) 4.7-6.1 5.5 0.25 4.6 
HOMA-IR 0.69-3.96 1.7 0.4 25.0 
fP-Total cholesterol (mmol/l) 3.61-6.55 4.81 0.35 7.4 
fP-HDL cholesterol (mmol/l) 0.91-2.35 1.74 0.13 7.0 
fP-LDL cholesterol (mmol/l) 0.89-4.10 2.46 0.30 12.8 
fP-Triglycerides (mmol/l) 0.59-2.79 1.36 0.12 8.3 
fP-Albumin* (g/l) 37-47 42 3.2 7.7 
fP-Ferritin* (µg/l) 14-140 62 10.7 19.1 
fP-ALT (U/l) 13-41 23 2.5 11.6 
fP-AST (U/l) 19-71 31 3.7 11.7 
fP-GGT (U/l) 10-52 20 2.5 11.3 
*not available from Pisa Research laboratory. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CV, 
coefficient of variation; fP, fasting plasma; fS, fasting serum; GGT, gamma-glutamyltransferase; HbA1c, glycated 
haemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; 
LDL, low-density lipoprotein; SD, standard deviation 
 
 
Table 9. Comparison of HOMA-IR measured in Helsinki and 6 other laboratories. 
 




HOMA-IR 2.0 in 
Helsinki corresponds to 
Newcastle, UK 0.93 <0.0001 <0.0001 ns 1.3 
Mainz, Germany 0.96 <0.0001 0.0004 ns 1.8 
Paris, France 0.99 <0.0001 ns ns 2.0 
Pisa (Clinical), Italy 0.96 <0.0001 0.009 ns 1.8 
Pisa (Research), Italy 0.87 0.001 ns ns 2.1 
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5.7. fS-pIGFBP-1 IN NAFLD (IV)  
 
Clinical characteristic of 378 subjects are 
shown in Table 2. The discovery (n=252) 
and validation (n=126) groups were 
comparable with respect to their clinical 
and biochemical parameters as well as 
PNPLA3 genotype at rs739409 (IV, Table 
1). 46% of the subjects had NAFLD. The 
median fS-pIGFBP-1 concentration was 
58 (32–106) µg/l. 
 
5.7.1. Correlation of liver fat and 
associated factors 
 
The variables were divided into groups 
measuring the same biological 
phenomena, as body composition, liver 
enzymes, lipids, glycaemia and 
insulinemia. In the discovery group, liver 
fat content was significantly inversely 
correlated with fS-pIGFBP-1 
concentration (ρ=-0.21, p=0.0009) and 
significantly positively correlated with age 
(ρ=0.25, p<0.0001), male gender (ρ=0.14, 
p=0.02) and the PNPLA3 I148M allele 
(ρ=0.16, p=0.01). Significant correlations 
were also found between liver fat content 
and liver enzymes (S-ALT [ρ=0.46, 
p<0.0001] and S-AST [ρ=0.37, 
p<0.0001]), measures of glycaemia (fP-
glucose [ρ=0.42, p<0.0001], and HbA1c 
[ρ=0.40, p<0.0001]) and measures of 
insulinemia (fS-insulin [ρ=0.46, 
p<0.0001] and fP-C-peptide [ρ=0.32, 
p<0.0001]). Of lipids, fS-triglycerides 
correlated positively (ρ=0.40, p<0.0001) 
and fS-HDL cholesterol inversely (ρ=0.32, 
p<0.0001) with liver fat content. 
Measures of body composition also 
correlated positively with liver fat content 
(waist-to-hip ratio [ρ=0.41, p<0.0001], 
body weight [ρ=0.20, p=0.002], BMI 
[ρ=0.17, p=0.005], waist circumference 
[ρ=0.28, p<0.0001], and body fat 
percentage [ρ=0.17, p=0.022], The 
variables with the best predictive value 
within each group of biological 
phenomena in the discovery group were 
thus S-ALT, fP-glucose, fS-insulin, fS-
triglycerides and waist-to-hip ratio. The 
correlation coefficient between fS-insulin 
and fS-pIGFBP-1 in all subjects was ρ=-
0.51, p<0.0001. 
 
5.7.2. Prediction of liver fat content 
 
The above-mentioned variables with the 
best correlations to liver fat content, 
among them age, gender, fS-pIGFBP-1 
and PNPLA3 genotype at rs738409, were 
evaluated by multivariate linear 
regression analysis to find independent 
associations in the discovery group. The 
significant variables and their possible 
interactions were examined. The final 
variables for multiple linear regression 
analysis were derived using a backward 
stepwise regression method. The 
significant variables were age, fS-pIGFBP-
1, an interaction term (age x fS-pIGFBP-
1), fS-ALT, waist-to-hip ratio, fP-glucose 
and fS-insulin, forming the ’% Liver fat 
equation’ (adjusted R2=0.44, p<0.0001). 
The adjusted R2 was 0.49 in the validation 
group and 0.47 in all subjects. If fS-
pIGFBP-1 was excluded, adjusted R2 was 
0.46 in all subjects (p<0.05 vs. the best 
model), and if fS-insulin was excluded, the 
adjusted R2 was 0.44 in all subjects 
(p<0.0001 vs. the best model). The 
correlation coefficient between predicted 
liver fat content using the ‘% Liver Fat 
Equation’ (IV, Table 3) and liver fat 
measured using 1H-MRS was ρ=0.62, 
p<0.0001 (Fig. 3).  
 
The ‘% Liver Fat Equation’ predicted liver 
fat significantly better than liver enzymes: 
AST only (adjusted R2=0.15), ALT only 
(adjusted R2=0.25), or both (adjusted 
R2=0.25, p<0.0001 for all comparisons). 
The AUROC (95% CI) to distinguish 
NAFLD from non-NAFLD with the ‘% 
Liver Fat Equation’ was 0.84 (0.80–0.88). 
This was significantly better than that of 
the FLI (0.72 [0.67–0.77], p<0.0001) or 
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The best predictors in univariate analysis 
within each group along with age, gender, 
fS-pIGFBP-1 and PNPLA3 genotype at 
rs738409 were also subjected to Random 
Forest modelling for prediction of liver fat 
(IV, Fig. 2). S-ALT, waist-to-hip ratio, fS-
insulin, fS-triglycerides and fS-pIGFBP-1 
were identified as the best five variables to 
explain variation in liver fat content 





























Figure 3. Correlation between liver fat percentages measured by 1H-MRS and estimated by ‘% Liver Fat Equation’ 
(ρ=0.62, p<0.0001). Adapted from Petäjä EM et al., Sci Rep 2016:6;24740 and reproduced with the permission of 
Nature Research Group.  
 






The prevalence of both MetS and NAFLD 
increases with obesity, and once fatty, the 
insulin-resistant liver overproduces the 
two key components of MetS, glucose and 
triglycerides (Yki-Järvinen, 2014). Almost 
half of people with NAFLD carry at least 
one variant (G) allele at rs738409 in the 
PNPLA3 gene, which is associated with 
high liver fat content, but is not 
accompanied by features of MetS 
(Sookoian and Pirola, 2011). All forms of 
NAFLD increase the risk of NASH, 
cirrhosis, and HCC. The present studies 
were undertaken to examine aspects of 
pathogenesis and diagnosis of NAFLD.  
 
6.1. ADIPOCYTE SIZE IN NAFLD  
 
In study I examining whether SC adipocyte 
size is a determinant of liver fat, the latter 
correlated with measures of obesity and 
insulin resistance, dyslipidemia, liver 
enzymes, PNPLA3 genotype and SC 
adipocyte size. Even though such 
univariate associations have been reported 
previously (Koska et al., 2008; Kotronen, 
Westerbacka, et al., 2007; Romeo et al., 
2008), the present data are novel as the 
independent contributions of the impact of 
SC adipocyte size as well as that of the 
PNPLA3 genotype on liver fat were 
examined. Prior to this study, two human 
studies have reported a positive correlation 
between SC adipocyte size and liver fat. 
O’Connell et al. reported a positive 
correlation between adipocyte size with the 
degree of hepatic steatosis as determined 
by histological assessment of samples from 
19 subjects undergoing bariatric surgery 
(O’Connell et al., 2010). Koska et al. 
measured, in 53 obese Pima Indians, SC 
adipocyte size and the liver/spleen 
attenuation ratio using CT, which provided 
a qualitative rather than quantitative 
measure of liver fat (Koska et al., 2008). 
Neither study determined the 
independence of the association or 
considered the PNPLA3 genotype. Since 
article I was published, two more studies 
have assessed liver steatosis and adipocyte 
size. Wree et al. studied 94 morbidly obese 
subjects undergoing bariatric surgery and 
found visceral adipocyte diameter to 
correlate positively with increasing NAS 
score (Wree et al., 2014). They did not 
report on whether the association was 
independent of other factors influencing 
liver fat content nor the relationship 
between adipocyte size and steatosis score 
(Wree et al., 2014). Jansen et al. measured 
liver fat content using 1H-MRS in 27 obese 
subjects with type 2 diabetes (mean BMI 
31 kg/m2) (Jansen et al., 2013). They 
found that liver fat content did not 
correlate with SC adipocyte size or 
measures of obesity (BMI, SC adipose 
tissue volume) but did correlate with 
markers of adipose tissue inflammation 
(Jansen et al., 2013). The lack of positive 
association between liver fat content and 
SC adipocyte size may be due to the 
difference in study populations (non-
diabetic vs. diabetic) and the small sample 
size. 
 
To study independent associations in 
multivariate analyses, results of the 
univariate analyses and pre-existing 
knowledge of causes and consequences of 
NAFLD were examined. The PNPLA3 
genotype (Romeo et al., 2008), age and 
gender (Kotronen, Westerbacka, et al., 
2007) and BMI (or fat mass or abdominal 
SC fat mass) were considered to be causes 
of variation in liver fat, while mild fasting 
hyperglycaemia and hypertriglyceridemia 
(resulting in low HDL cholesterol) were 
consequences rather than causes of hepatic 
insulin resistance. As discussed in the 
review of the literature (section 2.1.3.1), 
regarding the impact of gender on liver fat, 
women have significantly more SC and less 
IA fat for a given liver fat content than men 
do (Kotronen, Westerbacka, et al., 2007). 
However, men and women have equal 
amounts of liver fat if adjusted for the 
amount of IA adipose tissue volume. In the 





an independent predictor in the face of the 
other correlates of liver fat content. In 
multiple linear regression analyses, 
addition of adipocyte size into the model 
consisting of age, BMI, IA/SC adipose 
tissue ratio and the PNPLA3 genotype 
increased the explanatory power of the 
model from 42% to 53%, suggesting that 
adipocyte size contributes in a highly 
significant manner to the inter-individual 
variation in liver fat, although a cross-
sectional analysis cannot prove cause and 
effect. 
 
Adipocyte hypertrophy rather than obesity 
itself may be a key factor in the 
pathogenesis of adipose tissue 
inflammation. Adipocytes pushed to the 
limits of their ability to store lipids reach a 
genetically determined ‘critical size’, 
which leads to hypoxic stress and the 
release of higher levels of 
proinflammatory mediators, such as 
leptin and resistin, and lower amounts of 
adiponectin (Kershaw and Flier, 2004; 
Skurk et al., 2007) and the ensuing 
adipose tissue insulin resistance. 
Hypertrophied adipocytes secrete a 
surplus of pro-inflammatory cytokines, 
such as TNF-α and MCP-1 (Guilherme et 
al., 2008), that function as 
chemoattractants, leading to accumulation 
of macrophages and inflammation in 
adipose tissue (Zeyda and Stulnig, 2009). 
In line with this, adipocyte size is closely 
correlated with the number of 
macrophages in adipose tissue (Weisberg 
et al., 2003). Mice that lack HSL have 
hypertrophied adipocytes and macrophage 
infiltration in their adipose tissue despite 
being non-obese (Cinti et al., 2005), while 
apoptosis of hypertrophied adipocytes also 
promotes accumulation of macrophages in 
adipose tissue (Alkhouri et al., 2010). 
Inflammatory cytokines, such as TNF-α, 
disrupt insulin action in adipocytes, 
resulting in increased lipolysis and 
decreased triglyceride storage (Rydén and 
Arner, 2007). Hypertrophied adipocytes 
have higher lipolytic capacity than smaller 
adipocytes (Foley et al., 1997; 
Laurencikiene et al., 2011). In vitro, 
insulin sensitivity of human adipocytes 
was already 50 years ago shown to be 
inversely proportional to adipocyte size 
(Salans et al., 1968). As discussed earlier, 
insulin resistance in adipose tissue 
increases circulating FFA (Salans et al., 
1968), the key main substrate of 
intrahepatocellular triglycerides both in 
the fasting and post-prandial states 
(Donnelly et al., 2005).  
 
The liver is a physiologically likely 
mechanistic link between adipocyte size 
and alterations in circulating markers of 
the MetS, since fatty liver overproduces 
them (Kotronen and Yki-Järvinen, 2008; 
Kotronen et al., 2011). Thus, the 
independent relationship between 
adipocyte size and liver fat helps to explain 
why adipocyte hypertrophy correlates with 
features of insulin resistance independent 
of obesity and body composition (Hoffstedt 
et al., 2010; Weyer et al., 2000). The 
association between adipocyte size and 
liver fat may also help explain why both 
adipocyte hypertrophy (Lönn et al., 2010; 
Weyer et al., 2000) and liver fat (Lallukka 
and Yki-Järvinen, 2016) predict 
development of type 2 diabetes 
independent of obesity, gender and age. 
 
The current study is the first to study the 
relationship between SC adipocyte size and 
liver fat content independent of other 
known causes of liver steatosis. This is also 
the largest study reporting a positive 
correlation between adipocyte size and 
liver fat, as the previous studies comprised 
53 (Koska et al., 2008) and 19 (O’Connell 
et al., 2010) subjects. This study is cross-
sectional and hence cannot prove cause 
and consequence. Further studies are 
needed to establish whether adipocyte 
hypertrophy is in fact a predictor of 
development of NAFLD. Regarding the 
method used to determine adipocyte size, 
we measured the mean diameter of 100 SC 
adipocytes. This method is used frequently 
by others as well (Arner et al., 2010; 
Björnheden et al., 2004; Lönn et al., 2010; 




Lundgren et al., 2007) but provides a 
mean of less adipocytes than when using 
the osmium tetroxide and Counter 
method. Biopsies of intra-abdominal 
adipose tissue, although potentially 
interesting, were not taken from the 
healthy volunteers for ethical reasons, and 
hence we were not able to compare 
whether the association between IA 
adipocyte size and liver fat content differs 
from that of SC adipocyte size. 
 
6.2. DEFINITIONS OF NORMAL LIVER 
FAT 
 
As discovered in study II, the definitions of 
normal liver fat content vary, and are 
dependent on the method used, as they 
measure steatosis differently. In histologic 
assessment, a pathologist visually 
evaluates the percentage of hepatocytes 
with macroscopic lipid droplets, whereas 
1H-MRS quantifies the hepatic triglyceride 
content in a single voxel. MRI-PDFF also 
quantifies the hepatic triglyceride content, 
but does so on of all of the lobes of the 
liver. CT evaluates steatosis as the 
attenuation of liver and compared to that 
of the spleen, and US as a diffuse increase 
in parenchymal brightness and 
echogenicity of liver, thus give a qualitative 
estimate of degree of steatosis.  
 
1H-MRS remains the gold standard for 
quantifying liver fat content and is the 
most accurate method for assessing 
steatosis (Bohte et al., 2011). In the 
population-based DHS, the upper 95th 
percentile of the liver fat percentage in 
healthy subjects was 5.56% (Szczepaniak et 
al., 2005). In the present study, using the 
same criteria for the definition of healthy, 
and conducted on a selected, rather than 
population-based cohort, we found the 95th 
percentile to be 5.9%. In our Liver Fat 
Cohort, the prevalence of NAFLD was 35%, 
which is equivalent to the population 
prevalence of NAFLD at 33% in the DHS 
(Browning et al., 2004). Another study 
that included 170 healthy subjects found 
the 95th percentile to be 3.0% (Petersen et 
al., 2006). The authors speculated their 
lower value, compared to the DHS, might 
be because the subjects of their study 
might have been leaner, and the 
performance of 1H-MRS scanning differed, 
with the liver fat content in the DHS 
possibly being overestimated (Petersen et 
al., 2006). No population-based studies 
have been performed using the MRI-
PDFF, and therefore no gold standard 
definition exists, even though the method 
is widely used for research purposes. 
Definitions based on the 1H-MRS-derived 
5.6% (Reeder and Sirlin, 2010; Rehm et 
al., 2015) or 5.0% (Noureddin et al. 2013) 
are the most widely used.  
 
Liver steatosis is subject to some 
intrahepatic variation (Bannas et al., 
2015). Bannas et al. studied 13 ex vivo 
human livers, of which multiple biopsies 
were obtained and on which 1H-MRS and 
MRI-PDFF were performed. Depending on 
the location of the samples, histological 
macroscopic steatosis differed between 
10% and 25%, liver fat content measured 
using MRI-PDFF from 10% to 23% and 1H-
MRS from 12% to 20%. However, intra-
individually, the results of histological 
assessment remained mostly within the 
same steatosis grade (Bannas et al., 2015). 
 
None of the diagnostic cut-offs presented 
in Table 4 were based on metabolic or 
clinical outcomes of increased liver fat 
content. As the relationship between 
intrahepatic triglyceride content, measured 
using 1H-MRS, and metabolic function in 
obese subjects is in fact linear (Kotronen, 
Westerbacka, et al., 2007); Korenblat et al. 
2008), it is uncertain which value of liver 
fat actually has prognostic significance. 
 
Accurate quantification of steatosis is 
important for prospective longitudinal 
studies assessing the natural course of fatty 
liver, as well as treatment studies assessing 
the efficacy of medications (Chalasani et 
al., 2012; Musso et al., 2012; Noureddin et 





which assess steatosis qualitatively rather 
than quantitatively, are not applicable. US 
remains as a tool extensively used for 
screening purposes in the clinic, as more 
accurate methods are more costlier and 
not as widely available, even though its 
poor sensitivity in less than 30% of 
macroscopic liver fat is well known (Ryan 
et al., 2002). Due to radiation exposure, 
using CT as a screening tool is not 
recommended, even though it is more 
widely available, faster to perform and 
cheaper than MRI-based methods 
(Fierbinteanu-Braticevici, 2010). 
 
6.3. DEFINITIONS OF NORMAL 
INSULIN SENSITIVITY 
 
6.3.1 Insulin sensitivity in ‘Genetic NAFLD’ 
 
In the systematic review in study II, 
studies reporting markers of insulin 
sensitivity and liver fat ‘PNPLA3 NAFLD’ 
and ‘TM6SF2 NAFLD’ were identified. 
Regarding ‘PNPLA3 NAFLD’, 14 studies 
were identified. In 12 out of the 14, despite 
higher liver fat content or prevalence of 
hepatic steatosis, the carriers of PNPLA3 
I148M variant had similar or better insulin 
sensitivity than non-carriers of the variant. 
As previously shown, ‘PNPLA3 NAFLD’, 
even though it increases the risk of 
NAFLD, is not associated with features of 
MetS (Kantartzis et al., 2009; Kotronen, 
Johansson, et al., 2009; Romeo et al., 
2008; Sookoian et al., 2009). In study III, 
we found no difference in normal insulin 
sensitivity as defined by the 95th percentile 
of HOMA-IR in carriers and non-carriers 
of the PNPLA3 I148M variant in healthy 
subjects of two population-based cohorts. 
In non-diabetic subjects in whom liver fat 
content was measured using 1H-MRS, 
normal liver fat content being 5.56% as in 
DHS (Szczepaniak et al., 2005), the 
carriers of the variant had a significantly 
lower HOMA-IR in the face of similar liver 
fat content than the non-carriers. This is in 
line with the results from study II. 
Regarding the dissociation between 
hepatic steatosis and insulin resistance in 
‘PNPLA3 NAFLD’, our laboratory recently 
discovered in 125 morbidly obese subjects 
undergoing bariatric surgery, that the 
livers of carriers of the PNPLA3 I148M 
variant are enriched with polyunsaturated 
triglycerides whereas other lipids remained 
unchanged (Luukkonen, Zhou, Sädevirta, 
et al., 2016). In contrast, in NAFLD 
associated with insulin resistance, the liver 
was enriched with saturated and 
monounsaturated triglycerides and FFAs 
as well as dihydroceramides and 
ceramides, which are known to induce 
insulin resistance (Summers, 2006). This 
might in part explain why the ‘Metabolic’ 
but not ‘PNPLA3 NAFLD’ is associated 
with insulin resistance.  
 
In the systematic review in study II, 7 
studies that assessed both insulin 
sensitivity and liver fat in ‘TM6SF2 
NAFLD’ were identified. In 5 out of 7 of the 
studies, the carriers of the TM6SF2 E167K 
variant had higher liver fat content or 
higher prevalence of steatosis than the 
non-carriers without increased insulin 
resistance. In previous studies, the variant 
has been associated with lower circulating 
total and LDL cholesterol, and with lower 
triglyceride concentrations (Pirola and 
Sookoian, 2015) and with a lower risk of 
cardiovascular disease in carriers than 
non-carriers (Dongiovanni et al., 2015; 
Pirola and Sookoian, 2015). This has been 
hypothesised as caused by an impairment 
in the lipidation of VLDL (Smagris et al., 
2016). No studies regarding insulin 
resistance in ‘MBOAT7 NAFLD’ so far 
exist, but this will certainly be of interest in 
the future.  
 
Even though it has been shown that 
‘Genetic NAFLD’ is not associated with 
insulin resistance, subjects with it are not 
completely protected against it, but instead 
may be susceptible to both disorders (Yki-
Järvinen, 2014). Also, one may have more 
than one of the risk allele and be thus more 
susceptible to NAFLD. In 384 NAFLD 
patients and 384 age- and gender-matched 
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controls, when adding one risk allele of 
PNPLA3 or TM6SF2, the odds ratio for the 
risk of NAFLD was 1.64 (95% CI 1.34–
2.01), p<0.001. In the DHS, PNPLA3, 
TM6SF2 and MBOAT7 genotyping was 
performed on 2736 subjects, and liver fat 
content was shown to increase 
proportionally with increased number of 
risk alleles (Mancina et al., 2016). They did 
not report whether this increased risk of 
hepatic steatosis was associated with 
increased risk of insulin resistance.  
 
6.3.2 Reference value for HOMA-IR 
 
In study III, the healthy subjects of two 
population-based cohorts were identified, 
and the upper reference limit (95th 
percentile [90% CI]) for HOMA-IR was 1.9 
(1.8–2.0) in the FINRISK/DILGOM cohort 
and 2.0 (1.9–2.2) in the FIN-D2D cohort. 
 
Three previous studies attempting to 
define a reference value HOMA-IR have 
been performed in healthy subjects. These 
studies included fewer subjects considered 
healthy (161 Japanese subjects, 161 Italian 
subjects and 312 Brazilian subjects) than in 
the present study (456 to 1167 subjects) 
(Bonora et al., 1998; Geloneze et al., 2006; 
Nakai et al., 2002). In the Japanese study 
(Nakai et al., 2002), the 90th percentile of 
HOMA-IR was 1.7, which is comparable to 
that found in the present study. The Italian 
study, however, included diabetic and 
hypertensive subjects who thus cannot be 
considered healthy. The 80th percentile of 
HOMA-IR was 2.77 (Bonora et al., 1998). 
This study used the non-specific RIA by 
Linco Research Inc. (Missouri, US), which 
has given the highest insulin 
concentrations of several insulin assays 
tested (Manley et al., 2007; 2008). 
Similarly this RIA was used in the 
Brazilian study (Geloneze et al., 2006), 
and the 90th percentile of HOMA-IR was 
found to be equally high (2.71). Thus, the 
higher HOMA-IR values in these studies 
compared to the present study could be 
due to the inclusion of diabetic and 
hypertensive subjects in the Italian study 
and to both studies’ due to use of a RIA 
that is no longer used in most laboratories 
(Manley et al., 2007).  
 
We found no significant differences in 
HOMA-IR percentiles between men and 
women in the healthy subjects in either 
population-based cohort (Table 7). The 
men were, however, slightly more obese 
and older than the women, which is why 
we also calculated age- and BMI-adjusted 
HOMA-IRs. After adjustment, the men had 
slightly higher HOMA-IRs than the women 
in both studies, but the differences in 
absolute units were trivial (0.02 in the 
FINRISK and 0.05 in the FIN-D2D study). 
Previous population-based studies 
including healthy subjects did not report 
HOMA-IR values separately for men and 
women (Bonora et al., 1998; Geloneze et 
al., 2006; Nakai et al., 2002). Limitations 
of the use of HOMA-IR are discussed in 
section 6.4.2.  
 
6.4 DIAGNOSIS OF NAFLD 
 
6.4.1 HOMA-IR corresponding to normal 
liver fat content and the optimal HOMA-IR 
cut-off for NAFLD 
 
Study III was undertaken to determine 
whether a single value of HOMA-IR could 
be used to clearly identify subjects with 
NAFLD and how HOMA-IRs between 
laboratories in different European 
countries compare to each other. In 368 
subjects, whose liver fat content was 
determined using 1H-MRS, a HOMA-IR of 
1.9 was the best for discriminating subjects 
with NAFLD from those without based on 
the Youden Index. HOMA-IR of 2.0 
corresponded to normal liver fat content of 
5.56% defined as the upper limit of normal 
liver fat content in the DHS.  
In keeping with the 95th percentile in the 
healthy subjects in the population-based 
cohorts, a HOMA-IR of 1.9 was the best for 
distinguishing subjects with and without 





value corresponds to the results in 88 
healthy Brazilian subjects and 116 subjects 
with NAFLD diagnosed by ultrasound or 
biopsy (Salgado et al., 2010). As 
determined by our study, the Brazilian 
study found a HOMA-IR of 2.0 (AUROC 
0.84) to best distinguish between NAFLD 
and non-NAFLD subjects. Also, a study 
comprising 263 Columbian men found a 
HOMA-IR of 1.7 (AUROC 0.78) to be the 
cut-off for NAFLD (Perez et al., 2011). No 
previous studies in Caucasian populations 
have been performed. In linear regression 
analysis, a HOMA-IR of 2.0 corresponded 
to liver fat content of 5.56%. There was no 
significant difference between men and 
women. Even though ours was not a 
population-based study, the prevalence of 
hepatic steatosis was similar in the current 
cohort as in the Caucasian American 
population in the DHS using 1H-MRS (35% 
vs. 33%, respectively) (Browning et al., 
2004). Interestingly, in our cohort of 
healthy subjects who had undergone 1H-
MRS for measurement of liver fat content, 
the 95th percentile of liver fat was 5.9%, 
resembling the 5.56% found in the 
population-based DHS (Szczepaniak et al., 
2005). Our cohort was not population-
based and thus the 5.56% in the DHS can 
be considered more accurate than our 
estimate of 5.9%.  
 
The PNPLA3 I148M variant predisposes to 
NAFLD but not to features of MetS 
(Sookoian and Pirola, 2011). Thus, despite 
an increased liver fat content in PNPLA3 
I148M variant carriers, HOMA-IR has 
been similar in carriers and non-carriers of 
similar age, gender and BMI, as shown in 
Table 5. Consistent with these data, in both 
of the present two healthy population-
based cohorts, no difference existed in 
clinical characteristics between carriers 
and non-carries of the PNPLA3 I148M 
variant. The upper limit of normal HOMA-
IR was the same in the carries and non-
carriers. In the Liver Fat Cohort, in which 
35% of subjects had NAFLD, the optimal 
cut-off for distinguishing NAFLD from 
non-NAFLD was also not affected by the 
genotype. However, if carriers are 
compared to non-carriers with a similar 
liver fat content, the carriers of the variant 
have significantly lower HOMA-IR than 
the non-carriers (III, Fig. 2b). These data 
suggests that HOMA-IR cannot be used for 
diagnosing subjects with ‘PNPLA3 
NAFLD’, and that these subjects can only 
be identified by genotyping for this gene 
variant (EASL et al., 2016). 
 
6.4.2 Limitations in the use of HOMA-IR  
 
As presented in the introduction, HOMA-
IR is valid only as long as serum insulin 
concentrations reflect merely insulin 
sensitivity, not secretion (Bonora et al., 
2000; Borai, Livingstone, Farzal, et al., 
2010; Singh and Saxena, 2010). In subjects 
with non-diabetic glucose tolerance, 
fasting glucose and insulin concentrations 
have a close positive correlation (Lillioja et 
al., 1988). Once glucose tolerance becomes 
diabetic, insulin concentrations start to 
decline and the relationship to glucose 
becomes inverse rather than positive 
(Lillioja et al., 1988). Under such 
conditions, HOMA-IR underestimates 
insulin resistance associated NAFLD. As a 
fasting measure, HOMA-IR is also 
influenced by insulin clearance, unlike 
direct measurements of insulin sensitivity. 
However, this may not be a problem as the 
decrease in insulin clearance closely 
parallels that in hepatic insulin sensitivity 
(Kotronen, Vehkavaara, et al., 2007). 
 
Use of HOMA-IR in the clinic assumes that 
inter-laboratory variation in insulin assays 
is known (Manley et al., 2008). In the 
present study, we analysed fasting blood 
samples, after a similar period of freezing, 
thawing and time of storage, from 10 
individuals covering a wide range of 
HOMA-IR. Freezing and thawing the 
samples the same day had no significant 
impact on the values of fS-insulin but 
storage at -80°C degrees for 14 days caused 
a significant decrease in the values of fS-
insulin. From the regression lines relating 
the assay results of two laboratories, the 
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upper limit of normal HOMA-IR was 
similar in Helsinki and Paris, where the 
same insulin assay was used (2.0), but 1.3 
to 2.1 in the five other laboratories, which 
used different assays. The inter-laboratory 
CV was 25%, and this was due to the CV of 
fS-insulin (25.4%), not fP-glucose (5.4%). 
In contrast, the inter-laboratory CVs for 
other analytes, with the exception of 
ferritin, were much lower, ranging from 
5% to 14%. This is in line with a previous 
study by the Insulin Standardization 
Workgroup, which found an inter-
laboratory CV of 24% (Marcovina et al., 
2007).  
 
The results of this study imply that every 
laboratory has to establish its own 
reference value for HOMA-IR or at least 
know how the insulin assay compares with 
that of other laboratories. Furthermore, 
reference values for HOMA-IR, even of 
subjects defined as healthy, and the 
relationship between HOMA-IR and liver 
fat may be population-specific.  
 
6.4.3 Performance of fS-pIGFBP-1 as a non-
invasive predictor of liver fat content in 
NAFLD 
 
In study IV, it was shown that 
measurement of fS-pIGFBP-1 might help 
in the prediction of liver fat content in the 
face of other correlates of liver fat. The 
final model for predicting liver fat included 
age, fS-pIGFBP-1, an interaction term (age 
x fS-pIGFBP-1), S-ALT, waist-to-hip ratio, 
fP-glucose and fS-insulin. This study is the 
first to measure pIGFBP-1 rather than 
IGFBP-1 and in combination with other 
known predictors of liver fat content.  
 
In the previous studies measuring IGFBP-
1, the extent to which the assay measured 
phosphorylated forms of IGFBP-1 was not 
specified (Alderete et al., 2011; Maddux et 
al., 2006; Rajpathak et al., 2009; 
Savastano et al., 2011; Wasada et al., 
2008). In the present study, the median 
fS-pIGFBP-1 was 58 µg/l, which is similar 
to the earlier reported pIGFBP-1 
concentrations ranging from 29 to 100 
µg/l (Borai, Livingstone, Ghayour-
Mobarhan, et al., 2010; Coverley and 
Baxter, 1997; Heald et al., 2002). These 
concentrations are notably higher than 
those of lesser-phosphorylated IGFPB-1 
ranging from 4 to 12 µg/l (Borai, 
Livingstone, Ghayour-Mobarhan, et al., 
2010; Heald et al., 2002). The 
phosphorylation status of IGFBP-1 alters 
its antigenicity (Jones et al., 1991) and 
consequently some immunoassays may 
grossly underestimate changes in IGFBP-1 
concentrations (Mehta et al., 2012). 
Previous RIAs used for measuring IGFBP-
1 produced mean fS-IGFBP-1 
concentrations ranging from 16 to 20 µg/l 
(Kotronen, Lewitt, et al., 2008; Lewitt et 
al., 2010; Mohamed-Ali et al., 1999) and 
detected thus only a fraction of total 
IGFBP-1. In line with this, in the present 
study, both IGFBP-1 using RIA and 
pIGFBP-1 using IEMA were measured in 
the subset of 23 subjects. The mean 
concentration of fS-IGFBP-1 using RIA (18 
µg/l) was much lower than that of fS-
pIGFBP-1 using IEMA (58 µg/l). 
 
The inverse relationship between liver fat 
content and pIGFBP-1 is in line with 
earlier data in diverse groups measuring 
IGFBP-1 using RIA or an immuno-
radiometric assay (Alderete et al., 2011; 
Kotronen, Lewitt, et al., 2008; Savastano 
et al., 2011; Wasada et al., 2008). In the 
studies by Savastano et al. in 48 subjects 
(Savastano et al., 2011) and Kotronen et al. 
in 113 subjects (Kotronen, Lewitt, et al., 
2008), the correlation coefficients 
between fS-IGFBP-1 and hepatic steatosis 
score (US) or liver fat (1H-MRS) were in 
both studies -0.38 (p<0.01 or less). In the 
present study, the correlation coefficient 
between fS-pIGFBP-1 and liver fat (1H-
MRS) in 378 subjects was -0.27 
(p<0.0001). This was statistically 
comparable to the previous data in smaller 
groups of subjects (p=0.5 for r=-0.27 in 
378 subjects vs. r=-0.38 in 48 subjects 
(Savastano et al., 2011) and p=0.3 for r=-
0.27 in 378 subjects vs. r=-0.38 in 113 
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subjects (Kotronen, Lewitt, et al., 2008)). 
 
As discussed, causes (aging, body 
composition) and consequences 
(hyperinsulinemia, hypertri-glyceridemia, 
hyperglycaemia, elevated liver enzymes) of 
insulin resistance are known to be 
significantly associated with increased 
liver fat. Therefore, several variables 
rather than one alone should be examined 
when developing tools for non-invasive 
prediction of liver fat. In addition to the 
previously established markers, fS-
pIGFBP-1 was significantly associated with 
liver fat content in both univariate and 
multiple linear analyses. The PNPLA3 
I148M variant significantly associated 
with liver fat in univariate but not in 
multiple linear regression analyses. This 
might be due to the fact that the variant 
could signal its influence via increased S-
ALT, which remained a significant 
independent predictor in multiple linear 
regression analysis. Subjects with 
increased liver fat content were also 
hyperinsulinemic, possibly contributing to 
the observed inverse relationship between 
fS-Insulin and fS-pIGFBP-1. 
Consequently, the relationship could 
reflect inhibition of production of IGFBP-1 
in the liver by insulin (Brismar et al., 
1994). Hepatic insulin resistance could 
also influence the slope of the relationship 
between fS-insulin and fS-IGFBP-1. A 
fixed increment in serum insulin 
suppresses serum IGFBP-1 less in subjects 
who are insulin-resistant than in the 
insulin-sensitive (Kotronen, Lewitt, et al., 
2008). Of these two factors, i.e., insulin 
per se and hepatic insulin sensitivity, 
insulin might be more important in 
regulation of fS-IGFBP-1, as type 1 
diabetic patients who lack the portal-
peripheral insulin gradient have markedly 
higher fS-IGFBP-1 concentrations than 
matched non-diabetic subjects, even in 
cases where the latter have enhanced 
hepatic insulin sensitivity (Llauradó et al., 
2015; Yki-Järvinen et al., 1995).  
 
In line with the observed significant 
interaction between age and fS-pIGFBP-1, 
IGFBP-1 correlates with age independent 
of BMI (Rutanen et al., 1993). Aging 
associates with decreased suppression of 
IGFBP-1 by insulin (Rutanen et al., 1993). 
The variables that are used in equations to 
evaluate liver fat should be standardised in 
order to enable comparison between 
different laboratories and centres. 
Although fS-insulin is perhaps the most 
popular laboratory test for assessing 
insulin sensitivity, its assay procedures, as 
discussed earlier and shown in this study, 
are highly variable and have high a inter-
laboratory variation. The measurement of 
pIGFBP-1 for predicting pre-term delivery 
(Rahkonen et al., 2009; Riboni et al., 
2011) and of lesser-phosphorylated 
IGFBP-1 for the diagnosis of premature 
rupture of foetal membranes (Rutanen et 
al., 1996) have become worldwide 
standards and are produced by a single 
manufacturer. 
 
Limitations in the study are 
acknowledged. The study was cross-
sectional and thus cause and consequence 
cannot be proven. Also, even when a great 
number of factors known to be either 
causes or consequences of liver fat content 
were examined, a large proportion of the 
variation in the liver fat is unexplained. 
Direct measurement of liver fat content by 
widely available US would seem to be a 
more attractive tool. As discussed earlier, 
limitations of the use of US is that that the 
sensitivity is poor in subjects with low liver 
fat content (Ryan et al., 2002) and 
accuracy is weak in obese subjects (Mottin 
et al., 2004). Compared to measurement 
of e.g. liver enzymes alone, the ‘%Liver Fat 
Equation’ was much better in capturing 
information on liver fat. The AUROC of 
the ‘% Liver Fat Equation’ (0.84) was 
significantly better than that of the FLI 
(0.72) or the HSI (0.62). The ‘% Liver Fat 
Equation’ has been published as an online 
supplement and is available for calculation 
at www.nature.com/articles/srep24720 
(Petäjä et al., 2016).	




7 SUMMARY AND 
CONCLUSIONS 
 
The present studies were undertaken to 
gain further knowledge of the 
pathogenesis and diagnosis of NAFLD. 
 
Pathogenesis 
Regarding pathogenesis, we found 
abdominal SC adipocyte size to be 
associated with liver fat independent of 
other known associates, including obesity, 
adipose tissue distribution, PNPLA3 
genotype and age. This helps to explain 
why adipocyte hypertrophy has been 
associated with features of insulin 
resistance and of the metabolic syndrome 
independent of obesity and fat 
distribution. In addition, these data may 
also help to explain why both adipocyte 
hypertrophy and liver fat predict type 2 




Definitions of normal liver fat vary 
depending upon the diagnostic method 
used and do not correspond directly with 
each other. This needs to be considered 
when guidelines for diagnosis of NAFLD 
are established (II). 
 
NAFLD is heterogeneous. Insulin 
resistance characterises ‘Metabolic 
NAFLD’ and can be estimated using 
HOMA-IR. We found in two population-
based cohorts that the upper reference 
limit of HOMA-IR in healthy subjects is 
1.9-2.0. These values were not affected by 
gender or genetic variation in PNPLA3. In 
ROC-analysis, a HOMA-IR of 1.9 was the 
best for distinguishing between NAFLD 
and non-NAFLD. In linear regression 
analysis, normal liver fat content 
corresponded to a HOMA-IR of 2.0 with 
no differences between men and women. 
A HOMA-IR exceeding 2.0 in our 
laboratory thus suggests the patient has 
NAFLD. However, inter-laboratory 
variation in insulin assays and thus in 
HOMA-IR is high (III). In contrast to 
‘Metabolic NAFLD’, no difference in 
insulin sensitivity was observed in 14 
studies between carriers and non-carriers 
of the PNPLA3 I148M variant. Similarly, 
no difference in insulin sensitivity was 
observed in 7 studies comparing insulin 
sensitivity between carriers and non-
carriers of the TM6SF2 E167K variant (II). 
Carriers of the PNPLA3 I148M variant 
had significantly lower HOMA-IR in the 
face of similar liver fat content than the 
non-carriers. Use of HOMA-IR to 
diagnose NAFLD in carriers of these gene 
variants thus underestimates liver fat 
content. 
 
pIGFBP-1 helps in the prediction of liver 
fat content in NAFLD compared to 
routinely available clinical and 
biochemical parameters (IV). Its 
measurement may be helpful in 
diagnosing NAFLD. 
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